USO DE UM COMPLEXO MOLECULAR OU DE UMA COMPOSIÇÃO QUE COMPREENDE O COMPLEXO MOLECULAR PARA O TRATAMENTO DE CÂNCER
A molecular complex combining sulfated sugar and APC/NK/NKT cell ligands enhances immune activation, addressing the limitations of current ICP therapies by inducing potent immune responses and antitumor effects.
Patent Information
- Application Number
- BR112022023987
- Authority / Receiving Office
- BR · BR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-28
- Filing Date
- 2021-05-28
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-05-28
AI Technical Summary
Existing immunotherapies targeting immune checkpoint inhibitors (ICPs) are ineffective in a significant portion of cancer patients, necessitating the development of more effective immunomodulatory compounds that can selectively modulate immune responses without causing widespread side effects.
A molecular complex comprising a ligand of a sulfated sugar from the glycosaminoglycan family, such as heparan sulfate, linked with a ligand of antigen-presenting cell (APC) or NK/NKT cell surface molecules, which activates immune cells like dendritic cells and NK/NKT cells, enhancing cytokine secretion and immune activation.
The complex induces robust immune responses, including increased secretion of IL-6 and IL-12, and can surpass the therapeutic effects of anti-ICP antibodies, offering superior antitumor activity and broad applicability across various diseases.
Abstract
Description
1 / 72 USE OF A MOLECULAR COMPLEX OR A COMPOSITION COMPRISING THE MOLECULAR COMPLEX FOR THE TREATMENT OF CANCER FIELD OF TECHNIQUE
[001] The invention pertains to the field of modulating immunotherapies. The invention relates to a molecular complex consisting of at least one ligand of a sulfated sugar from the glycosaminoglycan family and at least one ligand of another molecule from the surface of antigen-presenting cells or NK or NKT cells, said ligands being linked together, for use as an immunomodulatory drug, in particular in the immunotherapy of cancer and infectious diseases. STATE OF THE ART
[002] Most therapeutic approaches rely on drugs that can act directly on the target responsible for the disease or on cells that exhibit a non-physiological state. However, disease processes can be promoted by dysfunctions of the immune system. In particular, immunosuppressive mechanisms are observed during tumor progression (Galon J. and D. Bruni, Nat. Rev. Drug Discov., 2019 18(3):197-218) or during infections with an infectious pathogen (Wherry EJ and M. Kurachi, Nature Rev. Immunol., 2015, 15(8):486-499). These observations have led to the development of immunotherapeutic drugs that can restore the proper functioning of immune defenses, particularly by modulating the activity of T lymphocytes or NK or NKT cells, in order to allow the immune system to more effectively control disease processes.The goal of these modulating immunotherapies is to restore or inhibit the functionality of a large part of the lymphocyte repertoire, particularly the repertoire of CD4+ T, CD8+ T, or regulatory T lymphocytes. In this sense, they differ from vaccine immunotherapies, which... Petition 870240042133, dated 05 / 17 / 2024, page 9 / 86 2 / 72 The objective is to induce a limited number of lymphocytes corresponding to specific cells of the antigen(s) included in the vaccine.
[003] To develop immunotherapeutic drugs, it is necessary to identify in advance targets that play a crucial role in controlling the immune response. Throughout the 1990s, it was demonstrated that molecules expressed on the surface of T lymphocytes, referred to respectively as PD-1 and CTLA-4, could induce inhibitory signals that downregulate the activity of these cells and could thus regulate certain immune defense mechanisms (Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). EMBO J., 11 (11), 3887-3895; Freeman, et al. (2000). J Exp Med, 192(7), 1027-1034; Krummel MF, Allison JP, J. Exp. Med., August 1, 1995;182(2):459-65). These two molecules have been termed immune checkpoint inhibitors, immune checkpoint inhibitor molecules, or ICP inhibitors.
[004] The molecular mechanisms responsible for the activity of these ICP inhibitors have been studied. In particular, it has been observed that PD-1 and CTLA-4 interact with ligands expressed on the surface of antigen-presenting cells (APCs) or tumor cells. These ligands are called PD-L1 and B7, respectively. The PD-1 / PD-L1 or CTLA-4 / B7 interaction then mediates inhibitory signals from T lymphocytes and, as a result, causes different immunosuppressive mechanisms. Furthermore, it has been demonstrated that PD-1, PD-L1, or CTLA-4 specific antibodies (Ab) could block the PD-1 / PD-L1 or CTLA-4 / B7 interaction, thus enabling the removal of inhibition and reactivation of T lymphocytes (Hodi, FS et al., PNAS. (2003), 100(8), 4712-4717; Iwai, Y et al., Int. Immunol., (2005). 17(2), 133-144). Some of these immunomodulatory Ab have proven capable of limiting the growth of various cancers (melanoma, lung cancer, etc.) and significantly increasing the life expectancy of patients.They are now commonly used as... Petition 870240042133, dated 05 / 17 / 2024, page 10 / 86 3 / 72 antitumor immunotherapy drugs in humans (Adachi K. and K. Tamada, Cancer Sci., 2015;106(8):945-50; Riley RS et al., Nat. Rev. Drug Discov. 2019 18(3):175-196). They are also envisioned for other therapeutic fields, particularly for the treatment of infectious diseases (Rao M. et al., Int. J. Infect. Dis., 2017;56:221-228). However, these early inhibitory anti-ICPs have the disadvantage of working only in 10 to 30% of cancer patients (Pitt JM et al., Immunity. June 21, 2016;44(6):1255-69). Thus, there are numerous research groups aiming to find new immunomodulatory compounds that are more effective and / or that can be used in combination with the immunotherapies described above.Since several new ICP inhibitors have been identified, research has focused on selecting compounds capable of binding to these ICPs or their ICP ligands and thus neutralizing the ICP / ICP ligand binding to reactivate T lymphocytes. The discovery of ICP activators expressed on the T cell surface has led to further research focusing on selecting agonist ligands to these ICPs (Mahoney KM. et al., Nat. Rev. Drug Discov., 2019, 14:561-584; De Sousa Linhares A., Front. Immunol., 2018, 31;9:1909; Granier C. et al., ESMO Open, July 3, 2017;2(2):e000213).
[005] In order to immunomodulate the immune response as effectively as possible, therapeutic molecules were sought that were able to bind to ICPs or ICP ligands selectively expressed on the surface of effector immune cells, such as T lymphocytes and NK or NKT cells, or antigen-presenting cells (APCs). This is because this selective expression allows limiting the spread of the molecule to non-immune cells. This results in increased therapeutic efficacy and a decreased risk of side effects.
[006] The glycocalyx is mainly composed of proteoglycans, which are glycoproteins comprising one or more unbranched chains of Petition 870240042133, dated 05 / 17 / 2024, page 11 / 86 4 / 72 glycosaminoglycan (GAG). Among the latter, the heparan sulfate proteoglycan (HSPG) family corresponds to proteins associated with sulfated GAGs: heparan sulfates (HS). HSPGs, which play a central role in numerous biological processes (cell proliferation, cell adhesion, inflammation, coagulation, cellular penetration of pathogenic microorganisms, particularly viruses and parasites), are found on the surface of most mammalian cells and in extracellular matrices (Dreyfuss et al., Annuals of the Brazilian Academy of Sciences, 2009, 81, 409-429). This ubiquitous expression, therefore, means that HSPGs and their HS domains are not considered relevant immunomodulatory targets. Furthermore, the ability of HS ligands to induce immune cell activation has not yet been identified. SUMMARY OF THE INVENTION
[007] During the course of their work, the inventors first discovered that a ligand of a sulfated sugar from the GAG family, heparan sulfate (HS), is unable to activate dendritic cells in vitro. They then observed that a molecular complex containing this ligand and a ligand of an antigen-presenting cell (APC) surface molecule potentiates the immunomodulatory effect of the heparan sulfate (HS) ligand. In fact, this molecular complex induces APC even more strongly, as shown by the increased secretion of the cytokines IL-6 and IL-12, and allows the subsequent activation of T lymphocytes. The inventors demonstrated that the association between the ligands can be produced in the form of a covalent or non-covalent complex, in particular in the form of a fusion protein.Furthermore, the inventors observed that the immunomodulatory properties of this complex allow for better control of disease processes and, in particular, slowing the progression of a tumor.
[008] These results are surprising because, although described as Petition 870240042133, dated 05 / 17 / 2024, page 12 / 86 5 / 72 capable of serving as a receptor or co-receptor, it had never been demonstrated that HSPGs could potentiate ligand-mediated activation of a receptor specifically expressed on the surface of APCs. Finally, the molecular complex that targets ubiquitously expressed HS can spread to the extracellular matrix or to cells of no interest to the disease. Thus, theoretically, it should not be able to modulate the activity of APCs and a large repertoire of T lymphocytes with sufficient efficacy for an immunotherapeutic effect to occur.
[009] The inventors also found that the results obtained with APCs could be transposed to other cells of the innate immune response, NK and NKT cells. Thus, the inventors demonstrated that a ligand of a surface molecule of NK or NKT cells, unable to induce these cells on its own, becomes capable of increasing the number of activated cells when associated, in a molecular complex, with a ligand of a sulfated sugar from the GAG family.
[010] Consequently, an object of the present invention is a molecular complex for use as an immunomodulatory drug, preferably an immunostimulant drug, said complex consisting of at least one ligand of a sulfated sugar from the glycosaminoglycan family (first ligand or L1) and at least one ligand of another APC or NK or NKT cell surface molecule (second ligand or L2), said ligands being linked together and said complex being free of a specific antigen of the disease to be treated.
[011] According to preferred embodiments of the invention, the first linker is a heparan sulfate-binding peptide selected from the group consisting of: a peptide derived from the HIV Tat protein, comprising at least the basic Tat 49 to 57 region (SEQ ID NO: 3), such as Petition 870240042133, dated 05 / 17 / 2024, page 13 / 86 6 / 72 the peptides Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8) and Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9); a polyarginine peptide R7 to R11; and a diphtheria toxin R domain-derived peptide, comprising the diphtheria toxin R domain (SEQ ID NO: 5) or at least the DT453 to 467 fragment (SEQ ID NO: 7) of said domain comprising the heparan sulfate-binding region.
[012] According to preferred embodiments of the invention, the second ligand targets a surface molecule of APCs selected from the group consisting of: C-type lectin receptors, membrane-bound immunoglobulins, receptors for the immunoglobulin constant region and immune checkpoint (ICP) molecules.
[013] According to preferred embodiments of the invention, the second ligand targets a surface molecule of NK or NKT cells selected from the group consisting of: NKG2D, NKp30, NKp44, NKp46, NKp80, Ly49H receptors, KIR, NKG2A and ICP receptors PD-1, CTLA-4, TIM-3, TIGIT, LAG3.
[014] The second ligand is preferably selected from the group consisting of: (i) antibodies directed against the aforementioned surface molecules of APCs or NK or NKT cells and fragments thereof containing at least the paratope; (ii) immunoglobulins, preferably IgG, and fragments thereof comprising at least the Fc region; and (iii) proteins and protein fragments that bind to the Fc and / or Fab region of antibodies, particularly S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) and the ZZ derivative thereof (SEQ ID NO: 2).
[015] According to preferred embodiments of the invention, said complex is in the form of oligomers or a mixture of monomers and oligomers.
[016] According to the preferred embodiments of the invention, the aforementioned Petition 870240042133, dated 05 / 17 / 2024, page 14 / 86 The 7 / 72 complex consists of a fusion protein between the first and second ligands. A type of complex that is more particularly preferred according to the invention consists of a fusion protein comprising a first ligand selected from: Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8), Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9), the R domain of diphtheria toxin (SEQ ID NO: 5) or the DT453 to 467 fragment (SEQ ID NO: 7) and a second ligand selected from: the BB fragment of protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2).
[017] According to other preferred embodiments of the invention, the second linker is an antibody or antibody fragment and the first linker forms a fusion protein with an immunoglobulin-binding element, preferably S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2). Preferably, the said fusion protein comprises a first linker selected from Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8), Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9), the R domain of diphtheria toxin (SEQ ID NO: 5) or the DT453 to 467 fragment (SEQ ID NO: 7) and an immunoglobulin-binding element selected from the BB fragment of protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2).In one type of complex that is particularly preferred according to the invention, the immunoglobulin-binding element is the BB fragment of protein A (SEQ ID NO: 1) and said fusion protein is complexed with a second ligand consisting of a whole immunoglobulin. In another type of complex that is particularly preferred according to the invention, said fusion protein is complexed with a second ligand that is selected from an anti-RFc gamma I, II and / or III, anti-DEC-205, anti-DC-SIGN, anti-CD74, anti-CD275, anti-CD335, anti-CD336, anti-CD56, anti-CTLA-4, anti-PD-L1, anti-OX40 antibody. Petition 870240042133, dated 05 / 17 / 2024, p. 15 / 86 8 / 72 or a fragment of the previous antibodies comprising at least the paratope.
[018] According to preferred embodiments of the invention, the complex is for use as an immunostimulant drug, preferably to activate antigen-presenting cells, particularly dendritic cells or monocytes, to activate NK or NKT cells and / or to activate the secretion of cytokines IL-6 and / or IL-12.
[019] Another object of the present invention is a composition for use as an immunomodulatory drug, preferably an immunostimulant drug, comprising at least one molecular complex according to the invention and at least one pharmaceutically acceptable carrier, a carrier substance and / or an adjuvant. The adjuvant is preferably a CpG oligodeoxynucleotide, polynosinic:polycylicitidylic acid or a mixture of CpG oligodeoxynucleotide(s) and polynosinic:polycylicitylic acid and / or the carrier substance is a nanoparticle.
[020] According to preferred embodiments of the invention, said composition comprises at least one other therapeutic agent, preferably at least one immune checkpoint inhibitor, preferably an anti-PD-1, an anti-PD-L1 or an anti-CTLA-4.
[021] According to preferred embodiments of the invention, the composition is for use in immunotherapy for cancer or infectious diseases. DISCLOSURE OF THE INVENTION
[022] An object of the present invention is a molecular complex for use as an immunomodulatory drug, preferably an immunostimulant drug, said complex consisting of at least one ligand of a sulfated sugar from the glycosaminoglycan family (first ligand) and by Petition 870240042133, dated 05 / 17 / 2024, page 16 / 86 9 / 72 minus a ligand from another APC or NK or NKT cell surface molecule (second ligand), said ligands being linked together, and said complex being free of a specific antigen of the disease to be treated.
[023] This complex is capable of favorably inducing immune system cells to trigger an immune response. Thus, when splenocytes are incubated with these complexes, activation of dendritic cells is observed, which become capable of secreting the cytokines IL-6 and IL-12. Furthermore, DC induction can be obtained for second ligands that are incapable of triggering such an effect when not associated, such as the isolated form of the APC ligand, called ZZ. The association of the HS ligand can also potentiate the effect of a ligand that is capable, in the isolated state, of activating APCs, such as a non-specific polyclonal human antibody. The association of the HS ligand with an NK or NKT cell ligand can also enable the activation of these cell types, whereas it lacks this capacity in its isolated form.Finally, an immunomodulatory complex, preferably an immunostimulatory complex according to the invention, can induce a therapeutic effect, in particular an antitumor effect, that is superior to that obtained with an anti-ICP (anti-PD1) antibody, particularly when the composition includes an adjuvant. DEFINITIONS
[024] “Innate immune response cells” are intended to mean dendritic cells, NK and NKT cells, granulocytes (mast cells, neutrophils, eosinophils and basophils) and phagocytes (monocytes, macrophages, neutrophils, etc.).
[025] “Antigen-presenting cell” (APC) is intended to mean a cell that presents Ag, a cell that expresses one or more class I and class II molecules of the major histocompatibility complex (MHC) (HLA class I and class II molecules in humans) and is capable of presenting the Ags Petition 870240042133, dated 05 / 17 / 2024, page 17 / 86 10 / 72 to CD4+ and CD8+ T lymphocytes specific for this antigen. As antigen-presenting cells, dendritic cells (DCs), monocytes, macrophages, B lymphocytes, lymphoblastoid cell lines, and genetically modified human or animal cell lines expressing MHC class I and class II molecules, particularly HLA I and HLA II molecules, can be mentioned in particular.
[026] “NK cell” is intended to mean a granular lymphocyte that expresses CD56 and CD16 molecules and has cytotoxic activity that does not require prior exposure to the Ag.
[027] “NKT cell” is intended to mean a granular lymphocyte that expresses NK cell markers, particularly the CD56 and CD16 molecules, and T lymphocyte markers, particularly the CD3 molecule. This cell has cytotoxic activity that does not require prior exposure to the Ag.
[028] “APC surface molecule” is intended to mean a molecule expressed on the surface of Ag-presenting cells.
[029] “NK or NKT cell surface molecule” is intended to mean a molecule expressed on the surface of NK or NKT cells.
[030] “APC-specific surface molecule” is intended to mean a molecule expressed substantially on Ag-presenting cells, i.e., expressed on a highly limited number of cells other than APCs. This is therefore a molecule that has a high level of expression specificity for APCs.
[031] “Specific surface molecule for NK or NKT cells” is intended to mean a molecule expressed substantially on NK or NKT cells, i.e., expressed on a highly limited number of cells other than NK or NKT cells. This is therefore a molecule that has a high level of expression specificity for NK or NKT cells. Petition 870240042133, dated 05 / 17 / 2024, p. 18 / 86 11 / 72
[032] “Glycosaminoglycan (GAG)” is intended to mean a linear polysaccharide composed of a repeating disaccharide that always contains a hexosamine (glucosamine (GIcN) or galactosamine (GaIN)) and another saccharide (glucuronic acid (GIcA), iduronic acid (IdoA), galactose (Gal)). Glucosamine is N-sulfated (GIcNS) or N-acetylated (GIcNac). Galactosamine is always N-acetylated (GalNac). Sulfated glycosaminoglycans are, in particular, simple polymers of GlcA, such as chondroitin sulfate, and copolymers comprising residues of GIcA and / or IdoA and / or Gal, such as heparin, heparan sulfate, dermatan sulfate, and keratan sulfate. GAG chains can be covalently linked to proteins (proteoglycans) that are expressed on the surface of mammalian cells and / or excreted into the extracellular matrix.The first ligand according to the invention binds to a sulfated sugar from the glycosaminoglycan family that is expressed on the surface of mammalian cells, including, inter alia, APCs and NK or NKT cells.
[033] “Ab” is intended to mean an immunoglobulin (IgG, IgM, IgA, IgD, IgE). The term Ab denotes a specific Ab, that is, an Ab directed against a particular molecule x (anti-molecule x Ab), particularly an APC surface molecule (anti-APC surface molecule Ab). The term immunoglobulin denotes a non-specific Ab.
[034] “Individual” is intended to mean a human or animal, preferably a human individual.
[035] “Ligand” of a molecule is intended to mean any agent capable of binding to that molecule with sufficiently high affinity to form a stable complex, in vitro and in vivo.
[036] “APC ligand” is intended to mean a ligand of a surface molecule of Ag-presenting cells.
[037] “NK cell ligand or NKT ligand” is intended to mean a ligand of a Petition 870240042133, dated 05 / 17 / 2024, p. 19 / 86 12 / 72 NK or NKT cell surface molecule. Heparan sulfate ligand is intended to mean an agent that binds to heparin with an optical density signal at least equal to 50% of the signal measured when ZZ-Tat 22 to 57C(22 to 37)s is incubated at 100 nM, pH 7.2, in the ELISA assay of Example 1.
[038] Antigen is intended to mean any substance that can be specifically recognized by the immune system and, in particular, by antibodies and immune system cells (B lymphocytes, CD4+ T lymphocytes, CD8+ T lymphocytes) and that is capable of inducing an immune response.
[039] Disease-specific antigen is intended to mean an antigen that induces an immune response directed specifically against the disease to be treated. This disease-specific immune response includes the production of antibodies and / or the induction of a cytotoxic T cell response (CD8+ T lymphocyte activation) or a helper T cell response (CD4+ T lymphocyte activation) directed against an antigen of a pathogen or tumor cell responsible for the disease to be treated.
[040] Immunomodulator is intended to mean an agent capable of controlling the immune response and, in particular, of upregulating or downregulating the relative response of different populations or subpopulations of immune cells, such as T and B lymphocytes, APCs, NK or NKT cells. The term immunomodulator encompasses the terms immunosuppressant and immunostimulant. Immunostimulant is intended to mean an agent capable of upregulating, that is, activating the relative response of different populations or subpopulations of immune cells, such as T and B lymphocytes, APCs, NK or NKT cells. The effect of the immunomodulator, preferably the immunostimulant, is exerted against a broad cellular repertoire. It is independent of the presence of a specific antigen of the disease to be treated, unlike a vaccine which requires the presence of a Petition 870240042133, dated 05 / 17 / 2024, page 20 / 86 13 / 72 specific antigen of the disease to be treated and induces a specific immune response to said antigen. While the use of an immunogen or vaccine is limited to the disease comprising the specific antigen of that disease, the immunomodulatory complex, preferably immunostimulatory, according to the invention, which is independent of the presence of a specific antigen of the disease to be treated, can be used in the immunotherapy of numerous diseases, such as cancer and infectious diseases.
[041] Peptide is intended to mean a sequence of natural or synthetic amino acids, optionally modified. The term peptide is used regardless of the size of the amino acid sequence.
[042] The molecular complex according to the invention consists of at least two ligands of APC or NK or NKT cell surface molecules, linked together: the first ligand, designated L1, targeting a sulfated GAG, and the second ligand, designated L2, targeting another APC surface molecule. The molecular complex according to the invention may comprise one or more L1 ligands and one or more L2 ligands linked together. According to certain preferred embodiments of the invention, the molecular complex consists of an L1 ligand linked to an L2 ligand.
[043] The molecular complex according to the invention, preferably an immunostimulant complex, is free of a specific antigen of the disease to be treated, such as a specific vaccine antigen of the disease to be treated. If one of the ligands of the complex according to the invention comprises a specific antigen of a disease to be treated, then the treatment of said disease with said complex is excluded from the invention.
[044] APC and NK or NKT cell ligands are molecules or complexes of molecules that are natural, recombinant, or synthetic, and are proteins in nature (protein, peptide, polypeptide) or lipids. Petition 870240042133, dated 05 / 17 / 2024, page 21 / 86 14 / 72 carbohydrate, nucleic acid or mixed (glycolipid, glycoprotein, lipoprotein) in nature. According to certain preferred embodiments of the invention, the first and second linkers are proteins, polypeptides or peptides, hereinafter referred to as peptides, which are preferably recombinant or synthetic. The recombinant proteins, polypeptides or peptides are advantageously produced in prokaryotic or eukaryotic cells in a suitable expression system, particularly suitable for the production of therapeutic proteins. For example, the recombinant proteins, polypeptides or peptides can be produced in E. coli or in HEK or CHO cells.
[045] The first and second ligands are associated or linked to each other by any suitable means. They may be covalently or non-covalently linked, directly or by a ligand, and thus form a molecular complex. The complex or molecular complex consists of two or more ligands and, optionally, appropriate ligand(s).
[046] The covalent association or linkage of ligands is generated, in particular, by covalent chemical coupling (formation of a covalent conjugate) or by the construction of a fusion protein (genetic fusion).
[047] The immunomodulatory complex, preferably an immunostimulating complex, is in monomeric, oligomeric or mixed form (mixture of monomers and oligomers). According to certain preferred embodiments of the invention, said complex is in oligomeric or mixed form.
[048] According to certain preferred embodiments of the invention, the immunomodulatory molecular complex, preferably an immunostimulatory complex, consists of a fusion protein between the first ligand(s) (L1) and the second ligand(s) (L2). The amino acid sequences of L1 and L2 are merged in the appropriate order, either directly or by a spacer. Petition 870240042133, dated 05 / 17 / 2024, p. 22 / 86 15 / 72 suitable peptide. Depending on the respective sizes of the amino acid sequences of L1 and L2, they are fused at their ends (N-terminal end of one sequence fused to the C-terminal end of the other sequence) or one sequence is inserted into the other sequence at a suitable site that does not have a deleterious effect on the binding of the ligand to the receptor expressed on the surface of APCs and NK or NKT cells.
[049] Non-covalent linkage is generated primarily by adsorption onto a nanoparticle. It can also be obtained using a molecule (ligand or linking element) that has a high and specific affinity for L1 or L2. This linker is covalently linked to one of the ligands to associate non-covalently with the other ligand. When one of the linkers is an antibody (Ab), the linker is, in particular, a protein or a protein fragment that binds to the Fc and / or Fab region of immunoglobulins, as described in application FR 2759296. Such immunoglobulin-binding elements include, in particular, the S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) and the ZZ derivative thereof (SEQ ID NO: 2), the first two proteins binding to the Fc and Fab regions of immunoglobulins, while ZZ binds only to the Fc region.For example, when one of the ligands is an Ab or an antibody fragment, the immunoglobulin-binding element is covalently linked (covalent chemical coupling or fusion protein) to the other ligand. The ligand can also bind to partners that are respectively coupled to L1 and L2; for example, the ligand is streptavidin, which binds to the biotinylated ligands L1 and L2 (L1 biotin / streptavidin / biotin-L2). The ligand's affinity for its partner in the L1-L2 complex is sufficient that it does not immediately dissociate from this complex in vivo.
[050] According to certain preferred embodiments of the immunomodulatory complex of the invention, preferably a complex Petition 870240042133, dated 05 / 17 / 2024, p. 23 / 86 16 / 72 immunostimulant, one of the ligands is an antibody or an antibody fragment and the other ligand forms a fusion protein with an immunoglobulin-binding element, preferably S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2). Preferably, the second ligand is an antibody or an antibody fragment and the first ligand forms a fusion protein with an immunoglobulin-binding element, preferably S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2).
[051] The immunomodulatory properties, preferably the immunostimulatory properties of the complex according to the invention, are evaluated by conventional immunological tests known to those skilled in the art, such as those described in the examples. The immunostimulatory properties are evaluated, in particular, by analyzing the expansion and / or activation of different populations or subpopulations of immune cells, such as CD4+ T lymphocytes, CD8+ T lymphocytes and B lymphocytes, monocytes, dendritic cells, including conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs), NK cells, NKT cells. The expansion is analyzed, in particular, using flow cytometry by means of markers suitable for the different cell populations to be analyzed.The activation of immune cells can be analyzed by detecting activation (CD69) and / or maturation (CD86) markers using flow cytometry or by evaluating cytokines secreted into the extracellular medium, particularly IL-6 and IL-12, using conventional assays such as ELISA. As mentioned above, the immunomodulatory effect, preferably the immunostimulatory effect, of the molecular complex according to the invention is independent of the presence of a specific antigen of the disease to be treated. Petition 870240042133, dated 05 / 17 / 2024, page 24 / 86 17 / 72
[052] The molecular complex according to the invention, preferably an immunostimulatory complex, binds to at least one sulfated sugar of the glycosaminoglycan family expressed on the surface of APCs, NK or NKT cells (sulfated GAG) and to another APC, NK or NKT surface molecule, in particular a specific surface molecule for APCs, NK or NKT cells. The sulfated GAG targeted by the first linker is preferably a heparan sulfate, a chondroitin sulfate, a dermatan sulfate or a keratan sulfate, preferably a heparan sulfate. The sulfated GAG linker (first linker) may be derived from a mammalian cell or a pathogenic microorganism, particularly a virus (adenovirus, cytomegalovirus, HIV, Sindbis virus), a bacterium (Mycobacterium bovis, Bordetella pertussis), a parasite (Leishmania sp.) or a toxin; in particular, it is a molecular complex of a molecule or a fragment thereof that binds to heparin and / or heparan sulfates. Such ligands are described, in particular, in “Heparan Binding Proteins” H. Edward Conrad, Academic Press, San Diego and London and Dreyfuss et al., Annuals of the Brazilian Academy of Sciences, 2009, 81, 409-429 (see, in particular, Table II). Examples of such ligands include, but are not limited to: endogenous GAG ligands (thrombin, urokinase, vitronectin, fibroblast growth factor, and others), the HIV Tat protein (SEQ ID NO: 10) and fragments thereof, in particular fragments comprising only the basic Tat region (Tat 49 to 57 (SEQ ID NO: 3)) or the basic Tat region and central region (core; Tat 38 to 48 (SEQ ID NO: 4)); the adenovirus penton-derived dodecahedron (Vivès et al., Virology, 2004, 321: 332-340); the HIV envelope protein or the V3 region of this protein (Roderiquez et al., J. Virol., 1995, 69, 2233-), the Sindbis virus envelope glycoprotein (Byrnes, AP et Griffin, DE, J. Virol., 1998, 2, 7349-7356) and the R domain of diphtheria toxin (DTR or DTRBD; fragment 382 to 535 of DT (SEQ ID NO: 5)); Lobeck et al., Infection and Immunity, 1998, 66,. Petition 870240042133, dated 05 / 17 / 2024, page 25 / 86 18 / 72 418-423). Mention may also be made of cell-penetrating peptides (CPPs) that bind to heparin, heparan sulfates and / or chondroitin sulfates, such as peptides that are highly rich in basic residues, particularly arginines, which include the aforementioned peptides derived from the basic region of the HIV Tat protein (Tat 49 to 57) and polyarginine peptides (R7 to R11), and also basic / amphiphilic peptides, such as peptides derived from the antenapedia protein homeodomain (penetratin; fragment 43 to 58 (SEQ ID NO: 6)).
[053] Alternatively, the first ligand is a natural or recombinant Ab directed against a sulfated GAG, preferably heparin, heparan sulfates or chondroitin sulfates, or a fragment of this Ab containing at least the paratope (Ag-binding domain), such as a Fab, Fab', F(ab')2, Fv or single-chain Fv (scFv), Fabc fragment and Fab fragment comprising a portion of the Fc domain. Such Ab are described, in particular, in Thompson et al., J. Biol. Chem., 2009, 284, 35621-35631 and van Kuppevelt et al., J. Biol. Chem., 1998, 273, 12960-12966. The said Ab or Ab fragment is preferably human or humanized.
[054] According to advantageous embodiments of the molecular complex, preferably an immunostimulant molecular complex, of the invention, the first linker is a heparan sulfate-binding peptide selected from the group consisting of: a peptide derived from the HIV Tat protein, comprising at least the basic Tat 49 to 57 region (SEQ ID NO: 3) such as the Tat 49 to 57 peptides (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8) and Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9); a polyarginine R7 to R11 peptide; and a peptide derived from the R domain of diphtheria toxin, comprising the R domain of diphtheria toxin (SEQ ID NO: 5) or at least the DT453 to 467 fragment (SEQ ID NO: 7) of said domain comprising the heparan sulfate binding region. Petition 870240042133, dated 05 / 17 / 2024, page 26 / 86 19 / 72 The first ligand is preferably a heparan sulfate-binding peptide selected from the group consisting of: a peptide derived from the HIV Tat protein, comprising at least the basic Tat 49 to 57 region (SEQ ID NO: 3), in particular the Tat 22 to 57C(22 to 37)s peptide (SEQ ID NO: 9) and a peptide comprising the R domain of diphtheria toxin (SEQ ID NO: 5).
[055] In advantageous embodiments of the molecular complex, preferably an immunostimulant molecular complex, of the invention, where the complex comprises the R domain of diphtheria toxin (DTR: SEQ ID NO: 5), then the domain is produced in mammalian cells, in particular in the form of a fusion protein with the second ligand or an immunoglobulin-binding element, so as to form oligomers.
[056] The other molecule expressed on the surface of APCs that is targeted by the second ligand is also a ubiquitous surface molecule other than a sulfated GAG; a surface molecule expressed substantially on immune cells of the innate or adaptive response including APCs, i.e., a surface molecule specific to immune cells of the innate or adaptive response including APCs; or a surface molecule expressed substantially on APCs, and in particular on dendritic cells, i.e., a surface molecule specific to APCs and, in particular, to dendritic cells.Among these surface molecules substantially expressed on APCs and, in particular, on dendritic cells, the following can be mentioned: MHC class II molecules, in particular the α and β chains and the γ chain or invariant chain (li, li fragment or CD74) of MHC II molecules; surface immunoglobulins or membrane-bound immunoglobulins; integrins, such as, in particular, CD11c and MAC1, transferrin receptors, C-type lectin receptors, such as, in particular, mannose receptor (CD206), DEC-205 (CD205), CD206, DC-SIGN (CD209), LOX1, dectin-1 (receptor). Petition 870240042133, dated 05 / 17 / 2024, p. 27 / 86 20 / 72 beta-glucan), dectin-2, Clec9A, Clec12A, DCIR2, FIRE and CIRE; receptors for the immunoglobulin constant region (FcR or RFc), in particular FcyR, such as FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD16); the TNF receptor superfamily, such as CD40; and complement receptors. Among the surface molecules substantially expressed on APCs, mention can be made of immune checkpoint (ICP) molecules and their ligands (ICP ligands) expressed on APCs, such as, but not limited to, PDL1, PDL2, CD155, CD80, CD86, CD40, OX40L, ICOSL (CD275), CD70 (Wykes MN, Nat. Rev. Immunol., 2018, 18:91-104).
[057] The other molecule expressed on the surface of NK or NKT cells that is targeted by the second ligand is also a ubiquitous surface molecule other than a sulfated GAG; a surface molecule substantially expressed on immune cells of the innate or adaptive response, including NK or NKT cells, i.e., a surface molecule specific to immune cells of the innate or adaptive response, including NK or NKT cells; or a surface molecule substantially expressed on NK or NKT cells, i.e., a surface molecule specific to NK or NKT cells. Among these surface molecules substantially expressed on NK or NKT cells, mention may be made, in particular, of: NKG2D, NKp30, NKp44, NKp46, NKp80, CD56, CD16, KIR, NKG2A and ICP PD-1, CTLA-4, TIM-3, TIGIT, LAG-3 and OX40 receptors.
[058] According to advantageous embodiments of the molecular complex, preferably an immunostimulatory molecular complex, of the invention, the second ligand targets a molecule substantially expressed on APCs and, in particular, on dendritic cells, i.e., a molecule with a surface specific to APCs and, in particular, to dendritic cells, preferably selected from the group consisting of: C-type lectin receptors, immunoglobulins Petition 870240042133, dated 05 / 17 / 2024, page 28 / 86 21 / 72 membrane-bound receptors for the constant region of immunoglobulins.
[059] According to other advantageous embodiments of the molecular complex, preferably an immunostimulatory molecular complex, of the invention, the second ligand targets a surface molecule of APCs selected from the group consisting of: C-type lectin receptors, membrane-bound immunoglobulins, receptors for the immunoglobulin constant region (FcR or FcR) and immune checkpoint (ICP) molecules and ligands thereof (ICP ligands).
[060] According to advantageous embodiments of the invention, the second ligand targets a surface molecule substantially expressed on NK or NKT cells, i.e., a surface molecule specific to NK or NKT cells, preferably selected from the group consisting of: NKG2D, NKp30, NKp44, NKp46, NKp80, CD56, CD16, KIR, NKG2A and ICP PD-1, CTLA-4, TIM-3, TIGIT, LAG-3 and OX40 receptors; preferably NKp44 (CD336), NKp46 (CD335), NCAM (CD56), CTLA-4 and OX40.
[061] The second ligand is, in particular, selected from saccharides that bind to C-type lectin receptors; immunoglobulins and fragments thereof comprising the constant region that binds to FcRs; proteins or protein fragments that bind to the Fc region and / or Fab region of membrane-bound immunoglobulins, as described in application FR 2759296, particularly S. aureus protein A, the BB fragment thereof (SEQ ID NO: 1) and the ZZ derivative thereof (SEQ ID NO: 2), preferably rZZ (SEQ ID NO: 2). Alternatively, the second ligand is an antibody directed against these APC and NK or NKT cell surface molecules, or a fragment of such an antibody containing at least the paratope (Ag-binding domain), such as Fab, Fab', F(ab'h, Fv or single-chain Fv (scFv), Fabc fragments and Fab fragment comprising a portion of the Fc domain. Petition 870240042133, dated 05 / 17 / 2024, page 29 / 86 22 / 72
[062] The antibody or antibody fragment is directed, in particular, against a specific surface molecule of innate or adaptive immune response cells, including APCs, NK cells and NKT cells, such as, but not limited to, PDL1, PDL2, CD155, CD80, CD86, CD40, OX40L, ICOSL (CD275), CD70; PDL1, PDL2, CD155, CD80, CD86, CD40, OX40L, ICOSL (CD275), CD70, PD-1, CTLA4, TIM-3, TIGIT, LAG-3; preferably PDL1 and ICOSL (CD275) or PDL1, ICOSL (CD275), CTLA-4 and OX40.
[063] The antibody or antibody fragment may also be directed against a specific surface molecule of APCs and, in particular, dendritic cells, such as an anti-cRF gamma antibody (I, II and / or III) or anti-C-type lectin receptor, in particular anti-DEC-205 or anti-DC-SIGN (CD209); anti-DEC205, anti-DC-SIGN (CD209) or anti-invariant li chain (CD74). The antibody may be an agonist or an antagonist of said surface molecule; for example, the antibody is an agonist of an activating surface molecule or an antagonist of an inhibitory surface molecule. Said antibody or antibody fragment is preferably human or humanized. Such antibodies are well known to those skilled in the art and are commercially available.
[064] According to advantageous embodiments of the molecular complex, preferably an immunostimulatory molecular complex, the second ligand is selected from the group consisting of: (i) antibodies directed against said antigen-presenting cell or NK or NKT cell surface molecules and fragments thereof containing at least the paratope, such as Fab, Fab', F(ab'h, Fv, scFv, Fabc and Fab fragments with at least one portion of the Fc domain; (ii) immunoglobulins, preferably IgG, and fragments thereof comprising at least the Fc region; and (iii) proteins and protein fragments that bind to the Fc and / or Fab region of antibodies, Petition 870240042133, dated 05 / 17 / 2024, page 30 / 86 23 / 72 particularly the S. aureus A protein, the BB fragment thereof (SEQ ID NO: 1) and the ZZ derivative thereof (SEQ ID NO: 2).
[065] Antibodies directed against the aforementioned antigen-presenting cell surface molecules are preferably selected from antibodies against cRF gamma (I, II and / or III), anti-DC-SIGN (CD209), anti-DEC-205, anti-CD206, anti-CD40; antibodies against cRF gamma (I, II and / or III), anti-DC-SIGN (CD209), anti-DEC-205, anti-CD206, anti-CD40, anti-invariant chain li (CD74) and anti-ICOSL (CD275); preferably, antibodies against DC-SIGN (CD209) and anti-DEC-205 or antibodies against DC-SIGN (CD209), anti-DEC-205, anti-invariant chain li (CD74) and anti-ICOSL (CD275).
[066] Antibodies directed against the aforementioned NK or NKT cell surface molecules are preferably selected from anti-CD16, anti-CD56, anti-CD335, anti-CD336, anti-NKp30, anti-NKG2D, anti-NKp80, anti-Ly49H, anti-NKG2A, anti-PD-1, anti-CTLA-4, anti-TIM-3, anti-TIGIT, anti-LAG-3 and anti-OX40 antibodies; preferably, anti-NCAM (CD56), anti-Nkp46 (CD335), anti-Nkp44 (CD336), anti-CTLA-4 and anti-OX40 antibodies.
[067] Additional ligands of the molecular complex, preferably an immunostimulatory molecular complex, are advantageously selected from sulfated GAG ligands and APC surface molecule ligands as defined above.
[068] A first type of preferred immunostimulant complex according to the invention consists of a sulfated GAG-binding peptide as defined above (first ligand) associated with a protein or protein fragment that binds to the Fc and / or Fab region of immunoglobulins, such as the BB fragment of Staphylococcus aureus protein A and the ZZ derivative thereof (second ligand), preferably in the form of a fusion protein comprising the first and second ligands. A first type of complex Petition 870240042133, dated 05 / 17 / 2024, page 31 / 86 A particularly preferred 24 / 72 consists of a fusion protein comprising a first linker selected from Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8), Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9), the R domain of diphtheria toxin (DTR: SEQ ID NO: 5) or the DT453 to 467 fragment (SEQ ID NO: 7); and a second linker selected from the BB fragment of protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2), preferably the ZZ derivative thereof (SEQ ID NO: 2). The first and second linkers are fused, either directly or by a suitable spacer peptide. In this first type of particularly preferred complex, the second ligand is preferentially at the N-terminal end, and the first ligand at the C-terminal end, of the fusion protein; the first and second ligands are separated by a suitable spacer peptide, particularly selected from SEQ ID NO: 21 to 23.More preferably, the complex in question comprises one of the sequences SEQ ID NO: 12, 14, 16, 18 and 20. When the complex comprises the R domain of diphtheria toxin (DTR: SEQ ID NO: 5), then the domain is advantageously produced in mammalian cells, in particular in the form of a fusion protein with the second ligand, so as to form oligomers.
[069] A second preferred type of immunostimulant complex according to the invention consists of: (i) a sulfated GAG-binding peptide as defined above (first linker) covalently linked to an immunoglobulin-binding element as defined above, in particular a protein or a protein fragment that binds to the Fc and / or Fab region of Ab, preferably only to the Fab region, such as the Staphylococcus aureus protein A and the BB fragment thereof, preferably in the form of a fusion protein comprising the first linker and the immunoglobulin-binding element, said first linker covalently associated with Petition 870240042133, dated 05 / 17 / 2024, p. 32 / 86 25 / 72 immunoglobulin-binding element, being complexed to (ii) an immunoglobulin, preferably an IgG, or a fragment comprising at least the Fc region (second ligand). Preferably a whole immunoglobulin, preferably a whole IgG. The first ligand and the immunoglobulin-binding element are fused, either directly or by a suitable spacer peptide. A second, particularly preferred type of complex consists of a fusion protein comprising a first ligand selected from Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8), Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9), the R domain of diphtheria toxin (DTR: SEQ ID NO: 5) or the DT453 to 467 fragment (SEQ ID NO: 7) and an immunoglobulin-binding element comprising the BB fragment of protein A (SEQ ID NO: 1), said fusion protein being complexed to a whole immunoglobulin.In this second type of particularly preferred complex, the immunoglobulin-binding element (BB) is preferably at the N-terminal end and the first ligand at the C-terminal end of the fusion protein; the immunoglobulin-binding element (BB) and the first ligand are separated by a suitable spacer peptide, particularly selected from SEQ ID NO: 21 to 23. More preferably, said complex comprises one of the sequences SEQ ID NO: 16 or 18. When the complex comprises the R domain of diphtheria toxin (DTR: SEQ ID NO: 5), then the domain is advantageously produced in mammalian cells, in particular in the form of a fusion protein with the immunoglobulin-binding element, so as to form oligomers.
[070] A third preferred type of immunostimulant complex according to the invention consists of: a sulfated GAG-binding peptide as defined above (first ligand), associated with an Ab selected from the group consisting of an anti-RFc gamma Ab (I, II and / or III), an anti-DEC-205 Ab, Petition 870240042133, dated 05 / 17 / 2024, page 33 / 86 26 / 72 an anti-DC-SIGN antibody (CD209), an anti-li-invariant chain antibody (CD74), an anti-ICOSL antibody (CD275), an anti-NKp46 antibody (CD335), an anti-NKp44 antibody (CD336), an anti-NCAM antibody (CD56), an anti-CTLA-4 antibody, an anti-PDL1 antibody, an anti-OX40 antibody, and a fragment of the above antibody comprising at least the paratope. Preferably, the sulfated GAG-binding peptide as defined above (first linker) is covalently linked to an immunoglobulin-binding element as defined above, in particular a protein or protein fragment that binds to the Fc and / or Fab region of immunoglobulins, such as the BB fragment of Staphylococcus aureus protein A and its ZZ derivative, preferably in the form of a fusion protein of the first linker with the immunoglobulin-binding element. The first linker and the immunoglobulin-binding element are fused, either directly or by a suitable spacer peptide.A third, particularly preferred type of complex consists of a fusion protein comprising a first ligand selected from Tat 49 to 57 (SEQ ID NO: 3), Tat 37 to 57 (SEQ ID NO: 8), Tat 22 to 57C(22 to 37)s (SEQ ID NO: 9), the R domain of diphtheria toxin (DTR: SEQ ID NO: 5) or the DT453 to 467 fragment (SEQ ID NO: 7) and an immunoglobulin-binding element comprising the BB fragment of protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2), said fusion protein being complexed to an anti-RFc gamma (I, II and / or III), anti-DEC-205, anti-DCSIGN, anti-CD74, anti-CD275, anti-CD335, anti-CD336, anti-CD56 antibody. anti-CTLA-4, anti-PDL1, anti-OX40 or a fragment of the aforementioned antibodies comprising at least the paratope.In this third, particularly preferred type of complex, the immunoglobulin-binding element (BB or ZZ) is preferably at the N-terminal end and the first ligand at the C-terminal end of the fusion protein; the immunoglobulin-binding element (BB or ZZ) and the first ligand are separated by a peptide. Petition 870240042133, dated 05 / 17 / 2024, p. 34 / 86 27 / 72 suitable spacer, particularly selected from SEQ ID NO: 21 to 23. More preferably, said complex comprises one of the sequences SEQ ID NO: 12, 14, 16, 18 or 20. When the complex comprises the R domain of diphtheria toxin (DTR: SEQ ID NO: 5), then the domain is advantageously produced in mammalian cells, in particular in the form of a fusion protein with the immunoglobulin-binding element, so as to form oligomers. Preferably, said complex comprises an anti-DEC-205, anti-DC-SIGN, anti-CD74, anti-CD275, anti-CD335, anti-CD336, anti-CD56, anti-CTLA-4, anti-PDL1 or anti-OX40 antibody.
[071] According to preferred embodiments of the invention, said complex is used as an immunostimulant, preferably to activate antigen-presenting cells, particularly dendritic cells or monocytes, to activate NK or NKT cells and / or to activate the secretion of cytokines IL-6 and / or IL-12.
[072] Another object of the invention is an immunomodulatory composition, preferably an immunostimulating composition, comprising at least one immunomodulatory complex, preferably an immunostimulating complex, according to the invention, and at least one pharmaceutically acceptable carrier, a carrier substance and / or an adjuvant.
[073] Pharmaceutically acceptable carriers are those that are conventionally used.
[074] Adjuvants are adjuvants for humoral and / or cellular immunity that are conventionally used in immunotherapy. Adjuvants are advantageously selected from the group consisting of: oil emulsions, mineral substances, bacterial extracts, saponin, alumina hydroxide, monophosphoryl lipid A, squalene and TLR ligands, in particular oligodeoxynucleotides comprising at least one CpG sequence. Petition 870240042133, dated 05 / 17 / 2024, page 35 / 86 28 / 72 (CpG oligodeoxynucleotide), which are TLR9 ligands, or polynosinic:polycylicityl acid (poly(l):poly(C) or poly l:C), which is a TLR3 ligand. According to preferred embodiments of the invention, said composition comprises at least one adjuvant, preferably a CpG oligodeoxynucleotide, polynosinic:polycylicityl acid or a mixture of CpG oligodeoxynucleotide(s) and polynosinic:polycylicityl acid.
[075] Carrier substances are those that are conventionally used. In particular, they are unilamellar or multilamellar liposomes, ISCOMs, virosomes (virus-like particles), saponin micelles, solid saccharide microspheres (poly(lactide-co-glycolide)) or of auriferous nature and nanoparticles. According to preferred embodiments of the invention, said composition comprises at least one carrier substance, for example, a nanoparticle or a mixture of nanoparticles.
[076] The immunomodulatory composition, preferably an immunostimulatory composition, according to the invention, comprises a complex comprising 2 or more ligands or a mixture of different complexes, said complex(es) being optionally linked to each other by covalent or non-covalent bonds and / or incorporated within or on the surface of a particle, such as a liposome, a virosome or a nanoparticle.
[077] According to particular embodiments of the invention, the composition comprises a polynucleotide or a mixture of polynucleotides encoding APC, NK or NKT ligands, which are proteins, polypeptides or peptides. The polynucleotide consists of a recombinant, synthetic or semi-synthetic nucleic acid that can be expressed in host cells to which the composition is administered. The nucleic acid may be DNA, RNA, particularly mRNA, a mixed nucleic acid (DNA / RNA) and may be Petition 870240042133, dated 05 / 17 / 2024, p. 36 / 86 29 / 72 modified. For example, said composition comprises a polynucleotide comprising a sequence encoding a fusion protein comprising at least the coding sequences of the first and second ligands, suitably fused in the frame and, optionally, a sequence encoding a ligand as defined above. Alternatively, the composition comprises a mixture of polynucleotides comprising at least a first polynucleotide comprising a sequence encoding the first ligand and a second polynucleotide comprising a sequence encoding the second ligand, said first or second nucleotides also comprising a sequence encoding a ligand as defined above.The aforementioned polynucleotide(s) are preferably inserted into one or more expression vectors comprising suitable transcriptional and / or translational regulatory sequences (promoter, transcription activator, transcription terminator, polyadenylation signal) for the expression of the first and second ligands, and optionally other ligands in vivo in individuals to whom the composition is administered. Several vectors that can be used in therapy are known per se. Use may be made, inter alia, of viral vectors (adenoviruses, retroviruses, lentiviruses, AAVs) and non-viral vectors (naked DNA), particularly a plasmid, into which the sequence of interest has been previously inserted. Alternatively, the aforementioned polynucleotide(s) are mRNA, preferably modified. The use of mRNA in therapy is well known to experts in the field (analyzed, for example, by Drew Weissman, Expert Reviews of Vaccines, October 2014, 1-17, doi: 10.1586 / 14760584.2015).973859).
[078] According to particular embodiments of the invention, the composition comprises cells modified by the composition according to the invention. For example, the cells are modified by a polynucleotide, a mixture of Petition 870240042133, dated 05 / 17 / 2024, page 37 / 86 30 / 72 polynucleotides or a vector as defined above, or loaded with a ligand complex as defined above. The cell is, in particular, a natural antigen-presenting cell, such as a dendritic cell, or an artificial antigen-presenting cell, such as exosomes derived from dendritic cells or vesicles derived from cells expressing the ligands of the molecular complex according to the invention. For example, the cells are antigen-presenting cells from an individual to be treated, particularly dendritic cells that are modified ex vivo before being readministered to the individual (ex vivo cell therapy).
[079] The immunomodulatory composition may further comprise at least one other therapeutic agent, particularly an anticancer agent, an anti-infective agent, another immunomodulatory agent, or a vaccine antigen specific to the disease to be treated, said vaccine antigen being advantageously associated with a carrier substance or included in a suitable vector. According to preferred embodiments of the invention, said composition further comprises at least one immune checkpoint inhibitor (Marin-Acevedo J. et al., 2018, Hematol. Oncol., 11:39) such as, but not limited to, an anti-PD-1, an anti-PDL-1, or an anti-CTLA4, particularly an antibody, preferably a monoclonal antibody, directed against the PD-1, PDL-1, or CTLA4 molecule, preferably the human hPD-1, hPDL-1, or hCTLA4 molecule.The composition according to the invention advantageously comprises an anti-PD-1 antibody, in particular an anti-PD-1 monoclonal antibody, preferably anti-hPD-1. According to other preferred embodiments of the invention, said composition further comprises at least one vaccine antigen specific to the disease to be treated, preferably associated with a carrier substance or included in a suitable vector. Petition 870240042133, dated 05 / 17 / 2024, p. 38 / 86 31 / 72
[080] The immunomodulatory composition, preferably an immunostimulatory composition, comprises an effective dose of complex(es), polynucleotide(s), vector(s), cell(s) that is / are sufficient to induce an immune response capable of producing a therapeutic effect on the disease to be treated, i.e., reducing the symptoms of this disease. This refers, in particular, to attenuating the consequences of the action of a pathogen (infectious or non-infectious) or, alternatively, reducing the growth of a tumor, in an individual treated with this composition. This dose is determined and adjusted based on factors such as the individual's age, sex, and weight. The immunomodulatory composition, preferably the immunostimulatory composition, according to the invention, is in a pharmaceutical form suitable for the chosen administration.The composition is generally administered following standard immunotherapy protocols, in doses and for a duration sufficient to induce an effective immune response against the disease being treated. Administration may be intratumoral, subcutaneous, intramuscular, intravenous, intradermal, intraperitoneal, oral, sublingual, rectal, vaginal, intranasal, by inhalation, or by transdermal application. The composition is in a pharmaceutical form suitable for the chosen administration.
[081] Isolated polynucleotides or those inserted into a plasmid vector are introduced into the individual to be treated using physical methods, such as electroporation, or by associating them with any substance(s) that allow passage through the plasma membrane, such as carriers, for example, nanocarriers, liposomes, lipids, or cationic polymers. Furthermore, it is advantageously possible to combine these methods, for example, using electroporation associated with liposomes.
[082] The immunomodulatory composition, preferably an immunostimulating composition, according to the present invention, is used in Petition 870240042133, dated 05 / 17 / 2024, page 39 / 86 32 / 72 immunotherapy, in particular antitumor or anti-infective immunotherapy. The immunomodulatory composition, preferably the immunostimulating composition, according to the present invention, is used preventively or curatively, i.e., to prevent a disease in individuals or to treat individuals suffering from a disease. According to the preferred embodiments of the invention, said composition is used curatively, i.e., to treat individuals suffering from a disease. It can be used in combination with other treatments, whether therapeutic or surgical, particularly in combination with other therapeutic agents as defined above, and the composition according to the invention and the other therapeutic agents can be administered simultaneously, separately or sequentially.
[083] According to preferred embodiments of the invention, the said composition is for use in the treatment of cancer. Cancers are any type of cancer that may benefit from immunotherapy, such as, but not limited to: breast, colon, prostate, esophagus, stomach, lung, ENT (ear, nose and throat), skin, ovarian, uterine, brain, liver or kidney cancers.
[084] According to other preferred embodiments of the invention, said composition is used in the treatment of infectious diseases, particularly those in which the infectious agents remain in the body. Infectious diseases are any type of infectious disease that can benefit from immunotherapy (Wykes MN et al., Nat. Rev. Immunol., 2018, 18:91104), such as, but not limited to: viral, bacterial, fungal or parasitic infections, particularly infections caused by HIV, HBV, HCV, Mycobacterium tuberculosis or Plasmodium falciparum. When said complex comprises Tat or a Tat fragment as defined above, then said composition is used in the treatment of infectious diseases other than infection. Petition 870240042133, dated 05 / 17 / 2024, page 40 / 86 33 / 72 for HIV (AIDS). When the said complex comprises DTR or a fragment of DTR as defined above, then the said composition is used in the treatment of infectious diseases other than diphtheria (infection by the diphtheria bacillus, Corynebacterium diphtheriae).
[085] The immunomodulatory composition, preferably the immunostimulating composition, according to the present invention, is used in conventional therapy or in cell therapy, or by a combination of the two approaches.
[086] Cell therapy comprises the preparation of antigen-presenting cells, particularly dendritic cells or NK or NKT cells, by a conventional protocol comprising isolating peripheral blood mononuclear cells (PBMCs) from a patient to be treated and culturing the dendritic, NK or NKT cells in the presence of molecular complex(es), polynucleotide(s), vector(s) as defined above. In a second step, the antigen-presenting, NK or NKT cells loaded with the aforementioned molecular complex(es) or modified by the aforementioned polynucleotide(s) or vector(s) are reinjected into the patient.
[087] Another object of the present invention is a method of immunotherapy, in particular an antitumor or anti-infective method, characterized in that it comprises administering an immunomodulatory composition, preferably an immunostimulating composition as defined above, to an individual by any suitable means as defined above.
[088] Another object of the present invention is the use of an immunomodulatory composition, preferably an immunostimulating composition as defined above, to prepare a medicament intended for immunotherapy, preferably antitumor or anti-infective immunotherapy.
[089] APC ligand complexes and NK or NKT cells according Petition 870240042133, dated 05 / 17 / 2024, page 41 / 86 34 / 72 with the invention are prepared by conventional techniques known to those skilled in the art, namely: - Ligands for APC and NK or NKT cell surface molecules can be produced by chemical synthesis or by expression of recombinant DNA in a suitable eukaryotic or prokaryotic cell system. Peptides or proteins can be synthesized in solid phase, according to the Fmoc technique originally described by Merrifield et al. (J. Am. Chem. Soc., 1964, 85, 2149) and purified by reverse-phase high-performance liquid chromatography. Polypeptides and proteins can be produced from the corresponding cDNA, cloned into a suitable eukaryotic or prokaryotic expression vector; the polypeptides or proteins produced in cells modified by the recombinant vector are purified by any suitable means, particularly by affinity chromatography. Antibodies directed against APC and NK or NKT cell surface molecules are well known and commercially available.For example, but not limited to, Ab antiCD205 (ns 555831); anti-CD206 (n° 555952); anti-CD209 (n° 551186); anti-HLADR (n° 555556) are available from BECTON-DICKINSON, while Ab antiCD56 is available from Biolegend (n° 304622) and Ab anti-CD335 (AM31284AFN) and anti-CD336 (n° AM50346PU-N) are available from Origene. Alternatively, monoclonal antibodies can be produced by conventional techniques known to those skilled in the art. For example, monoclonal antibodies are produced from hybridomas obtained by fusing B lymphocytes from an animal immunized with the APC surface molecule with myelomas, according to the technique of Kohler and Milstein (Nature, 1975, 256, 495-497); hybridomas are cultured in vitro, particularly in fermenters, or produced in vivo in the form of ascites; alternatively, said monoclonal antibodies are produced by genetic engineering as described in the patent. Petition 870240042133, dated 05 / 17 / 2024, p. 42 / 86 35 / 72 US 4,816,567. Humanized antibodies are produced by general methods, such as those described in international application WO 98 / 45332. Antibody fragments are produced from cloned Vh and Vl regions of mRNA from hybridomas or splenic lymphocytes of an immunized animal; for example, Fv, scFv, or Fab fragments are expressed on the surface of filamentous phages according to the technique of Winter and Milstein (Nature, 1991, 349, 293-299); after several selection steps, antigen-specific antibody fragments are isolated and expressed in a suitable expression system by conventional techniques for cloning and expressing recombinant DNA. The antibody or fragments thereof, as defined above, are purified by conventional techniques known to those skilled in the art, such as affinity chromatography.
[090] The covalent association of the first ligand (L1) to the second ligand (L2) of a surface molecule of APCs or NK or NKT cells can be produced by constructing a fusion protein in which the nucleotide sequences encoding L1 and L2 are fused into the frame in the appropriate order, either directly or by a nucleotide sequence encoding a suitable spacer peptide. Depending on the respective sizes of the amino acid sequences of L1 and L2, they are fused at their ends (N-terminal end of one sequence fused to the C-terminal end of the other sequence) or one sequence is inserted into the other sequence at a suitable site that does not have a deleterious effect on the binding of the ligand(s) to the receptor expressed on the surface of APCs or NK or NKT cells. Alternatively, the ligand(s) may be covalently coupled by any suitable means.Coupling is produced by reaction groups that are initially present or introduced into the ligand(s) beforehand. Coupling can occur, in particular, in amino acid residues whose side chain comprises a reactive function. Among these amino acids... Petition 870240042133, dated 05 / 17 / 2024, page 43 / 86 36 / 72 mention may be made of polar amino acids comprising a function, as follows: -OH [serine (S), threonine (T) or tyrosine (Y)], -SH [cysteine (C)], NH2 [lysine (K) or arginine (R)], -COOH [aspartic acid (D) or glutamic acid (E)] and polar amino acids having a side chain functionalized by the addition of a reactive function, particularly a chloroacetyl or bromoacetyl group that reacts with thiol groups or a hydrazine group that reacts with aldehydes. The ligand is coupled by any suitable means; these means, which are known to those skilled in the art, include, in particular, coupling using homobifunctional reagents, such as glutaraldehyde or dithiobis(succinimidyl propionate). Preferably, the coupling is produced using heterobifunctional reagents, particularly m-maleimidobenzoyl-N-hydroxysuccinimide (SMCC) or sulfo-SMCC, each containing a maleimide group capable of reacting with free thiols.In this case, SMCC is previously covalently linked to an amine function present in the ligand. Simultaneously, another heterobifunctional reagent (such as N-succinimidyl-S-acetylthioacetate containing a thioester group that can be cleaved with hydroxylamine or succinimidyl-pyridyldithiopropionate containing a disulfide bridge that can be reduced under mild conditions) is associated with an amine function of the second partner, which is one of the ligands. The second partner is subsequently treated with hydroxylamine or a reducing agent to allow the release of the thiol. The thiolated compound is then incubated with the compound that has maleimide incorporated into it, and the coupling is achieved by the reaction of the thiol group with the maleimide group. This type of covalent coupling is described, in particular, in Léonetti et al., J. Exp. Med., 1999, 189, 1217-1228. It is also possible to release a thiol group already present in one of the compounds and then couple it to another previously modified compound using SMCC.This method, which is frequently used to couple Ab to ligands, is described, in particular, in Ishikawa et al., J. Petition 870240042133, dated 05 / 17 / 2024, page 44 / 86 37 / 72 Immunoassay, 1983, 4, 209-327.
[091] Non-covalent complexes are prepared by placing the second ligand (L2) in contact with the first ligand (L1) under conditions that allow the two partners to interact. This interaction may involve a ligand, particularly a protein or peptide, that has a high and specific affinity for one of the partners in the complex (L1 or L2). In particular, the ligand's affinity for this partner in the complex is sufficient that it does not immediately dissociate from this complex in vivo. When one of the ligands is an immunoglobulin, the ligand is an immunoglobulin-binding element as described in application FR 2759296. For example, an immunoglobulin-binding element is covalently linked to L1 so as to form a non-covalent complex with L2.
[092] The polynucleotides according to the invention are obtained by conventional methods that are known per se, according to standard protocols known to those skilled in the art. For example, they can be obtained by amplification of a nucleic acid sequence by PCR or RT-PCR, by screening genomic DNA libraries by hybridization with a homologous probe, or by total or partial chemical synthesis. The recombinant vectors are constructed and introduced into host cells by conventional recombinant DNA and genetic engineering methods that are known per se.
[093] Unless otherwise indicated, the implementation of the invention uses conventional methods of immunology, cell culture, cell biology, molecular biology and recombinant DNA that are known to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS Other features, details, and advantages of the invention will become available. Petition 870240042133, dated 05 / 17 / 2024, page 45 / 86 38 / 72 apparent from reading the following detailed description which refers to exemplary implementations of the present invention, and from analyzing the attached drawings, in which: Fig. 1
[094] Fig. 1 shows the molecular weight and degree of homogeneity of the molecular complexes produced in E. coli in HEK cells. The proteins ZZDTRBDhek, ZZ-DTRBDcoli, BB-DTRBDhek, BB-DTRBDcoli and ZZ-Tat 22 to 57C(22 to 37)s were analyzed by electrophoresis under denaturing conditions. The proteins were deposited in the presence of molecular weight markers. After electrophoretic migration, the proteins were stained with Coomassie blue. Fig. 2
[095] Fig. 2 shows the binding of several molecular complexes to heparin. Serial dilutions of free ZZ, ZZ-DTRBDhek, ZZ-DTRBDcoli, BB-DTRBDhek, BB-DTRBDcoli and ZZ-Tat proteins 22 to 57C(22 to 37)s were respectively incubated at pH 7.2 in wells of microtiter plates, previously adsorbed with rabbit IgG. After 4 hours, the plates were washed and biotinylated heparin was added. After 30 minutes of incubation, heparin binding to the plates was detected using streptavidin coupled to peroxidase and a substrate of this enzyme (ABTS). Heparin binding is considered significant when the optical density signal is at least equal to 50% of the signal measured when ZZ-Tat 22 to 57C(22 to 37)s is incubated at 100 nM, pH 7.2, in microtiter plates. Fig. 3
[096] Fig. 3 shows the cell types linked by the ZZDTRBDhek fusion protein in a population of mouse splenocytes. Splenocytes were incubated in the presence or absence of a fixed amount of ZZDTRBDhek (100 nM). A series of fluorescent Ab specific to CD11 b+ pDC, cDC and CD8+ cDC (A); CD4+ T lymphocytes, CD8+ T lymphocytes, B lymphocytes, monocytes (B) Petition 870240042133, dated 05 / 17 / 2024, page 46 / 86 39 / 72 was then added. After 30 minutes at 4 °C, the cells were washed and analyzed by flow cytometry. The percentage of cells bound by ZZDTRBHek in the subpopulation in question is shown. Fig. 4
[097] Figure 4 shows that ZZ-DTRBDhek induces the secretion of IL-6 and IL-12 by splenocytes. A fixed amount of ZZ, DTRBD or ZZ-DTRBDhek (1 μM) was incubated with mouse splenocytes. After 24 h, the supernatants were removed and the presence of IL-6 and IL-12 was evaluated by enzyme immunoassay. Fig. 5
[098] Figure 5 shows that ZZ-Tat 22 to 57C(22 to 37)s induces the secretion of IL-6 and IL-12 by splenocytes. A fixed amount of ZZ, TatcY49 to 57, ZZ + TatcY49 to 57 or ZZ-Tat 22 to 57C(22 to 37)s (1 μM) was incubated with mouse splenocytes. After 24 h, the supernatants were removed and the presence of IL-6 and IL-12 was evaluated by enzyme immunoassay. Fig. 6
[099] Figure 6 shows that the proteins ZZ-DTRBDhek and BB-DTRBDhek induce the secretion of greater amounts of IL-6 and IL-12 by splenocytes than ZZDTRBDcoli and BB-DTRBDcoli. A fixed amount of ZZ-DTRBDhek, ZZ-DTRBDcoli, BB-DTRBDhek, and BB-DTRBDcoli (1 μM) was incubated with mouse splenocytes. After 24 h, the supernatants were removed and the presence of IL-6 and IL-12 was evaluated by enzyme immunoassay. Fig. 7
[100] Figure 7 shows that ZZ-DTRBDhek induces the secretion of IL-6 and IL-12 by isolated murine dendritic cells. Dendritic cells were isolated by magnetic sorting. Dendritic cells were then incubated in the presence or absence of a fixed amount of ZZ-DTRBDhek (0.6 μM). After 24 Petition 870240042133, dated 05 / 17 / 2024, page 47 / 86 After 40 / 72 h, the supernatants were removed and the presence of IL-6 and IL-12 was evaluated by enzyme immunoassay. Fig. 8
[101] Figure 8A-B shows that the proteins ZZ-DTRBDhek and ZZ-Tat 22 to 57C(22 to 37)s are capable of inducing dendritic cell expansion in mice. Three groups of mice were injected three days apart with PBS buffer in the absence or presence of a fixed amount of ZZ-DTRBDhek (5 nmol per mouse) or ZZ-Tat 22 to 57C(22 to 37)s (10 nmol per mouse). 24 h after the final injection, the animals were euthanized and the spleens were removed and the splenocytes labeled with a fluorescent Ab cocktail, allowing to distinguish cDC-CD8+ (CD11altoB220-CD8+CD11b-) (A), cDC-CD11b+ (CD11altoB220-CD8-CD11b+) (B) and pDC (CD11cintCD317+CD11b+).
[102] Fig. 8C shows the cells analyzed by flow cytometry. The number of positive cells was shown as a percentage of the total number of live splenocytes. Statistical analysis was performed using the Kruskal-Wallis test (*p<0.05). Fig. 9
[103] Figure 9 shows that ZZ-DTRBDhek induces IL-6 and IL-12 secretion in vitro by isolated human DCs. Isolated DCs from healthy human donors were incubated in the presence of a fixed amount of ZZDTRBDhek (1 μM). After 24 h, the supernatants were collected to assess the presence of IL-6 and IL-12 cytokines by enzyme immunoassay. Fig. 10
[104] Figure 10 shows that mice injected with colorectal cancer cells exhibit retarded tumor growth when subsequently injected with ZZ-DTRBDhek alone or in combination with an adjuvant mixture. A: Sixteen C57BL / 6 mice were injected Petition 870240042133, dated 05 / 17 / 2024, page 48 / 86 41 / 72 subcutaneously with 0.5 M MC38 cells. Three days later, eight mice were injected with the adjuvant mixture CpG-B 1018 / Poly l:C (30 μg for each adjuvant) and eight were not injected (controls). A second injection was performed three days later. B: Eighteen C57BL / 6 mice were subcutaneously injected with 0.5 M MC38 cells. Three days later, six mice were injected with ZZ-DTRBDhek in PBS buffer, another six were injected with ZZ-DTRBDhek (2 nmol per mouse) in PBS buffer containing the adjuvant mixture CpGB 1018 / Poly l:C (30 μg for each adjuvant), and six were not injected (controls). Two additional injections were performed three days apart. Tumor growth was monitored by measuring the tumors using calipers. Each injection is represented by an arrow. Fig. 11
[105] Figure 11 shows that mice injected with colorectal cancer cells exhibit retarded tumor growth when subsequently injected with ZZ-DTRBDhek, ZZ-Tat 22 to 57C(22 to 37)s in association with an adjuvant mixture. Thirty-two C57BL / 6 mice were injected subcutaneously with 0.5 M MC38 cells. Three days later, a group of eight mice was injected with ZZ-DTRBDhek (0.96 nmol per mouse) in 50 μL of PBS containing the adjuvant mixture CpG-B 1018 / Poly l:C (30 μg for each adjuvant), another group with an anti-PD-1 antibody (50 μL, 1.3 nmol per mouse), a third group with ZZ-Tat 22 to 57C(22 to 37)s (0.96 nmol per mouse) in 50 μL of PBS containing the adjuvant mixture CpG-B 1018 / Poly l:C (30 μg for each adjuvant), and a final group of eight mice was not injected (controls). Two additional injections were performed three days apart. Tumor growth was monitored by measuring the tumors using calipers.Each injection is represented by an arrow. Petition 870240042133, dated 05 / 17 / 2024, page 49 / 86 42 / 72
[106] [Fig. 11A] Kinetics of tumor growth.
[107] [Fig. 11B] Kinetics of tumor growth.
[108] [Fig. 11C] Survival of treated animals. Fig. 12
[109] Fig. 12 shows that the formation of the molecular complexes ZZ-Tat 22 to 57C(22 to 37)s, anti-DEC205 / ZZ-Tat 22 to 57C(22 to 37)s and IgG / ZZ-Tat 22 to 57C(22 to 37)s induces, in vitro, an increase in the proportion of activated monocytes and CD4+ T lymphocytes. A fixed concentration (0.1 μM) of Ab anti-DEC205 / ZZ-Tat 22 to 57C(22 to 37)s, IgG / ZZ-Tat 22 to 57C(22 to 37)s, anti-DEC205 / ZZ, IgG / ZZ, anti-DEC205 was incubated with human PBMCs. A fixed concentration (1 μM) of ZZ-Tat 22 to 57C(22 to 37)s or ZZ was incubated with human PBMCs. After 24 h, the cells were collected and labeled using fluorescent Ab. The proportion of activated monocytes (CD3CD14+) in the live PBMC population was assessed using the CD69 marker.
[110] [Fig. 12A] The proportion of activated CD4+ T lymphocytes in the live CD4+ T lymphocyte population (CD3+CD4+) was assessed by measuring the expression of the CD69 molecule.
[111] [Fig. 12B] The cells were analyzed by flow cytometry. Fig. 13
[112] Figure 13 shows that molecular complexes targeting receptors expressed by dendritic cells (anti-CD74 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD209 / ZZ-Tat 22 to 57C(22 to 37)s and anti-CD275 / ZZ-Tat 22 to 57C(22 to 37)s) induce IL-6 secretion by PBMCs. Human PBMCs were incubated in the presence or absence of free forms of Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37)s and also molecular complexes targeting CD74 (A), CD209 (B) and CD275 (C), respectively. After 24 h, the supernatants were removed and the presence of IL-6 was assessed by enzyme immunoassay. Fig. 14 Petition 870240042133, dated 05 / 17 / 2024, p. 50 / 86 43 / 72
[113] Fig. 14 shows that a molecular complex (anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s) directed against the CD335 receptor expressed by NK and NKT cells induces an increase in the proportion of activated NK and NKT cells. PBMCs were incubated in the presence or absence of free forms of Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37)s and also the molecular complexes anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD335 / ZZ. After 18 h, the cells were analyzed by cytometry to evaluate the expression of the co-stimulatory molecule CD69 on the surface of NK cells (A) and NKT cells (B). Fig. 15
[114] Figure 15 shows that molecular complexes directed against two receptors expressed by NK and NKT cells respectively induce an increase in the proportion of activated NKT cells. PBMCs were incubated in the presence or absence of free forms of Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37)s, anti-CD56 / ZZ, anti-CD336 / ZZ-Tat 22 to 57C(22 to 37)s or anti-CD336 / ZZ molecular complexes. After 18 h, the cells were analyzed by cytometry to evaluate the expression of the co-stimulatory molecule CD69 on the surface of NKT cells. Fig. 16
[115] Figure 16 shows that molecular complexes targeting receptors expressed by NK cells (anti-CD56 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s and anti-CD336 / ZZ-Tat 22 to 57C(22 to 37)s) induce IL-6 secretion by human PBMCs. PBMCs were incubated in the presence or absence of free forms of Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37)s and molecular complexes targeting CD56 (A), CD335 (B) and CD336 (C), respectively. After 24 h, the supernatants were removed and the presence of IL-6 was assessed by enzyme immunoassay. Fig. 17 Petition 870240042133, dated 05 / 17 / 2024, p. 51 / 86 44 / 72
[116] Figure 17 shows that molecular complexes containing anti-ICP antibodies (anti-CTLA-4 / ZZ-Tat 22 to 57C(22 to 37)s, anti-PD-L1 / ZZ-Tat 22 to 57C(22 to 37)s and anti-OX40 / ZZ-Tat 22 to 57C(22 to 37)s) induce IL-6 secretion by human PBMCs. PBMCs were incubated in the presence or absence of free antibodies, ZZ or ZZ-Tat 22 to 57C(22 to 37)s and molecular complexes targeting CTLA-4 (A), PD-L1 (B) and OX40 (C), respectively. After 24 h, the supernatants were removed and the presence of IL-6 was assessed by enzyme immunoassay. EXAMPLES Example 1: Expression of fusion proteins in E. coli or HEK cells, purification, biochemical characterization, and study of their ability to bind to heparan sulfates. MATERIALS AND METHODS Production of different molecular complexes
[117] The expression of the ZZ-DTRBD fusion protein in E. coli, referred to as ZZ-DTRBDcoli, was previously described in the publication by Lobeck et al. (Infection and Immunity, 1998, 66, 418-423). The ZZ-DTRBDcoli fusion protein (SEQ ID NO: 12) is encoded by a polynucleotide that has the sequence SEQ ID NO: 11. The expression of the ZZ-Tat 22 to 57C(22 to 37)s fusion protein in E. coli was produced according to a protocol similar to that described for the ZZOVATat 22 to 57S fusion in the publication by Knittel et al. (Vaccine, 2016, 34(27):3093-3101). The ZZ-Tat 22 to 57C(22 to 37)Scoli fusion protein (SEQ ID NO: 20) is encoded by a polynucleotide with the sequence SEQ ID NO: 19. For expression in eukaryotic cells, HEK cells (2.5 x 10⁶ cells / mL in 250 mL of freestyle 293F medium) were transfected with a pCDNA3.4 plasmid encoding ZZ-DTRBHek (400 μg of DNA from a maxiprep transfection preparation) in the presence of PEI (0.5 mg / mL).This plasmid comprises the... Petition 870240042133, dated 05 / 17 / 2024, page 52 / 86 45 / 72 polynucleotide having the sequence SEQ ID NO: 13 which encodes the ZZ-DTRBDhek fusion protein (SEQ ID NO: 14). The cells were subsequently incubated for 24 hours at 37 °C with shaking. 250 mL of Ex-Cell medium were then added. After 4 days of incubation at 37 °C with shaking, the culture supernatants were recovered, filtered under sterile conditions, and a protease inhibitor cocktail was added.
[118] After expression of the three proteins, the supernatants were respectively diluted to ½ in 0.1% PBS-Tween and then passed through an IgG sepharose column (IgG sepharose 6Fast Flow No. 17-0969-02, Amersham) to purify the molecular complexes by immunoaffinity. The acidity of the fusion proteins eluted from the column was neutralized in 1 M Tris-HCl buffer, pH 8. The fusion proteins originating from expression in E. coli, ZZ-DTRBDcoli and ZZ-Tat 22 at 57C(22 to 37)s, were subjected to a second purification cycle using a mono S 5 / 50 cation exchange column (GE Healthcare). The column was equilibrated with 0.05 M phosphate-citrate buffer, pH=5.5, for the purification of ZZ-DTRBDcoli. The column was equilibrated with 0.05 M phosphate-citrate buffer, pH=4 for the purification of ZZ-Tat 22 at 57C(22 to 37)s. The fusion proteins ZZ-DTRBDcoli and ZZ-Tat 22 at 57C(22 to 37)s were subsequently eluted with a linear gradient from 0 to 1 M NaCl.The proteins were finally concentrated in PBS and stored at -20 °C until use. The molecular complexes BB-DTRBDhek and BBDTRBDcoli were produced according to the same protocol as used for ZZ-DTRBDhek and ZZ-DTRBDcoli. The BB-DTRBDhek fusion protein (SEQ ID NO: 18) is encoded by the polynucleotide sequence, SEQ ID NO: 17. The BB-DTRBDcoli fusion protein (SEQ ID NO: 16) is encoded by the polynucleotide sequence, SEQ ID NO: 15. Analysis of the molecular weight and degree of homogeneity of the molecular complexes ZZ-DTRBDhek, ZZ-DTRBDcoli, BB-DTRBDhek and BB-DTRBDcoli by Petition 870240042133, dated 05 / 17 / 2024, page 53 / 86 46 / 72 gel electrophoresis
[119] The proteins ZZ-DTRBDhek, ZZ-DTRBDcoii, BB-DTRBDhek and BB-DTRBDcoli and also the molecular weight markers were deposited on 4 to 12% SDS-PAGE gel under denaturing conditions and then subjected to electrophoretic migration. After migration, the presence of protein bands was revealed by staining with Coomassie blue. Binding of molecular complexes to heparin
[120] To evaluate the binding of molecular complexes to heparan sulfates, heparin was used, which is a sulfated sugar that represents the heparan sulfate family.
[121] The interaction was evaluated using an enzyme immunoassay technique. For this, a series of microtiter plates was previously adsorbed with rabbit IgG (1 μg / 100 μL / well in 0.1 M phosphate buffer, pH 7.2) and then saturated with a buffer solution containing 0.3% bovine serum albumin (200 μL / well in 0.1 M phosphate buffer, pH 7.2). Another series of microtiter plates was saturated with a buffer solution containing 0.3% bovine serum albumin (300 μL / well in 0.1 M phosphate buffer, pH 7.2). The two series of plates were subsequently washed and serially diluted (in 0.1 M phosphate buffer, pH 7.4, containing 0.1% bovine serum albumin) of the proteins ZZ-DTRBDHEK, ZZ-DTRBDcoli, BB-DTRBDHEK and BB-DTRBDcoli and ZZ-Tat 22 at 57°C (22 to 37) if free ZZ were deposited in the wells. After 4 hours of incubation at room temperature, the plates were washed and 100 μL of heparin-biotin (1 μM) were added per well.After 1 hour at room temperature, the plates were washed and 100 μL of streptavidin coupled to peroxidase (1 / 2000 dilution) were added. After 30 minutes of incubation, the plates were washed and a substrate (ABTS) was added. Staining was measured at 414 nm after 30 minutes of incubation. To eliminate nonspecific binding to albumin, the... Petition 870240042133, dated 05 / 17 / 2024, page 54 / 86 47 / 72 The optical signal measured on plates adsorbed only with bovine serum albumin was subtracted from the signal measured on plates adsorbed with IgG. Heparin binding is considered significant when the optical density signal is greater than or equal to 50% of the signal measured when ZZ-Tat 22 to 57C(22 to 37)s is incubated at 100 nM, pH 7.2, in microtiter plates. RESULTS
[122] The inventors previously constructed a fusion protein, referred to as ZZ-DTRBD, incorporating a double ZZ domain derived from Staphylococcus aureus protein A and also the DTRBD domain derived from diphtheria toxin (Lobeck et al., Infection and Immunity, 1998, 66, 418-423). ZZ can bind to the Fc region of immunoglobulins in a manner similar to protein A. As for DTRBD, it binds to the diphtheria toxin receptor and also has a heparan sulfate binding site located in the 453 to 467 region (Knittel et al. J. Immunol., 2015, 194(8):3601-11; Knittel et al. Vaccine, 2016, 34(27):3093-3101). These characteristics allow ZZ-DTRBD to target different types of cells that carry surface immunoglobulins and proteoglycan heparan sulfates by interacting with heparan sulfates.
[123] Similarly, the inventors constructed a fusion protein, referred to as BB-DTRBD, replacing the sequence encoding ZZ with an encoding sequence referred to as BB. The BB protein corresponds to a double domain that, like ZZ, is derived from the A protein of Staphylococcus aureus, but has the particular characteristic of binding to the Fc region and also to the Fab region of immunoglobulins (Jansson 1998 FEMS Immunol. and Med. Microbiol., Léonetti et al. 1999, J. Exp. Med., 189, 1217-28).
[124] The inventors also constructed a fusion protein, referred to as ZZ-Tat 22 to 57C(22 to 37)s. It contains a double ZZ domain derived from Staphylococcus aureus protein A and a Tat 22 to 57C(22 to 37)s derived from Petition 870240042133, dated 05 / 17 / 2024, p. 55 / 86 48 / 72 HIV transcriptional transactivator (WO 2011 / 092675 and Knittel et al. Vaccine, 2016, 34(27):3093-3101) which has a heparan sulfate binding site. These features allow ZZ-Tat 22 to 57C(22 to 37)s to target different cell types that carry surface immunoglobulins and proteoglycan heparan sulfates by interacting with HS.
[125] The inventors recombinantly expressed ZZ-DTRBD, BBDTRBD, and ZZ-Tat 22 to 57C(22 to 37)s using different expression systems. The complexes expressed in E. coli are referred to as ZZ-DTRBDcoli, BB-DTRBDcoli, and ZZ-Tat 22 to 57C(22 to 37), and those expressed in HEK cells are named ZZDTRBDhek and BB-DTRBDhek. After expression, the complexes were purified using a column containing a gel carrying IgG. Then, the ZZDTRBDcoli, BB-DTRBDcoli, and ZZ-Tat 22 to 57C(22 to 37)s proteins were subjected to ion-exchange chromatography to eliminate contaminating LPS. Finally, some characteristics of these complexes were evaluated by gel electrophoresis. As can be seen in Fig. 1, ZZ-DTRBDcoli and BB-DTRBDcoli migrate in a predominant band with a molecular weight of approximately 35 kDa, which is close to the theoretical weight of the molecule (32230), indicating that this band corresponds to a monomer.Smaller bands corresponding to degradation products are also present in these two molecular complexes. ZZDTRBDhek and BB-DTRBDhek migrate in several bands distributed substantially between 35 and 150 kDa, indicating that expression in HEK cells leads to a heterogeneous mixture consisting of monomeric and oligomeric forms of ZZ-DTRBD. The ZZ-Tat 22 to 57C(22 to 37)s molecular complex migrates in a predominant band, reflecting the homogeneity of the purified protein.
[126] The molecular weight of approximately 25 kDa is slightly greater than that calculated for the theoretical weight of the molecule (MW=19 145). However, Tat Petition 870240042133, dated 05 / 17 / 2024, pp. 56 / 86 49 / 72 and derivatives thereof tend to migrate abnormally (Kittiworakarn et al. etc.), strongly suggesting that the ZZ-Tat 22 to 57C(22 to 37)s fusion protein expressed in E. coli and purified consists substantially of a monomer.
[127] Next, the inventors studied the aptitude of free ZZ and the five molecular complexes to bind to heparin, which is a sulfated polysaccharide representing the heparan sulfate family. Enzyme immunoassay does not allow the observation of a significant optical signal for free ZZ (Fig. 2). In contrast, an increase in optical density based on the incubated dose is measured for ZZ-DTRBDcoli, BB-DTRBDhek, BB-DTRBDcoli, ZZ-DTRBDhek and ZZ-Tat 22 to 57C(22 to 37)s. These data therefore indicate that the presence of the DTRBD domain or the Tat 22 to 57C(22 to 37)s domain allows the molecular complexes to bind to heparin. Furthermore, since the ZZ-DTRBDhek and BB-DTRBDhek fusions contain oligomers (see Figure 1), these data indicate that the presence of oligomers does not disrupt the interaction. Example 2: The ZZ-DTRBDhek fusion protein is capable of binding to different types of cells in the murine immune system. MATERIALS AND METHODS ZZ-DTRBD binding to immune system cells
[128] Mouse C57BI / 6 splenocytes are resuspended at 10x106 cells / mL in PBS buffer, 0.5% BSA and 2 mM EDTA. 100 μL of the cell suspension are deposited in a 96-well round-bottom plate. 100 μL of buffer, 0.5% BSA and 2 mM EDTA are added per well in the absence or presence of ZZ-DTRBHek (100 nM). The mixtures are incubated for 30 minutes at 4 °C and then washed twice in PBS, 0.5% BSA and 2 mM EDTA. Two μg per well of rabbit IgG are added to the cells, which are incubated for 20 minutes at 4 °C and then washed twice with qs of 200 μL of PBS, 0.5% BSA, and 2 mM EDTA. The cells are resuspended in 50 μL of labeling buffer. Petition 870240042133, dated 05 / 17 / 2024, page 57 / 86 50 / 72 (PBS, 0.5% BSA, and 2 mM EDTA) containing different BioLegend Ab mixtures. The mixtures are incubated for 20 minutes at 4°C in the dark, and then the splenocytes are washed twice in qs of 200 μL of PBS, 0.5% BSA, and 2 mM EDTA. The cells are then fixed for 30 minutes at room temperature. For this purpose, 100 μL of 4% PFA buffer and then 100 μL of PBS, 0.5% BSA, and 2 mM EDTA were added before detection in the BD FACSAria™ cytometer.
[129] Mixture 1 for dendritic cells (duplicates): B220-FITC (no. 103206, 1 / 200), CD11 c-PE-Cy7 (no. 117318, 1 / 200), CD317-APC (no. 127016, 1 / 100), CD8a-PerCP-Cy5.5 (no. 100734, 1 / 200), CD11b-APC-Cy7 (no. 101226, 1 / 800), donkey anti-rabbit-BV421 (no. 406410, 1 / 100), Live Dead Aqua (ThermoFischer no. L34966, 1 / 1000).
[130] Mixture 2 for monocytes and T, B lymphocytes (duplicates): B220-FITC (ns 103206, 1 / 200), CD19-BV650 (n° 115541, 1 / 100), CD3-APC-Cy7 (n° 100222, 1 / 100), CD4-BV605 (n° 100451, 1 / 200), NK1. 1 -PE-Cy7 (n° 108714, 1 / 100), CD8aPerCP-Cy5. 5 (no. 100734, 1 / 200), CD11b-APC (no. 101212, 1 / 800), Ly6C-PE no. 128007, 1 / 800), donkey anti-rabbit-BV421 (no. 406410, 1 / 100), Live Dead Aqua (ThermoFischer no. L34966, 1 / 1000). RESULTS
[131] To evaluate the ability of a molecular complex to bind to immune system cells, ZZ-DTRBDhek was incubated in the presence of mouse splenocytes. It was therefore possible to observe that this fusion protein preferentially binds to cDC-CD8+ cells, which are specialized APCs (Fig. 3A). It also preferentially interacts with monocytes, which can also serve as APCs (Fig. 3B). Finally, it binds to a lesser extent to lymphocytes. These data therefore indicate that the fusion protein preferentially targets APCs. Petition 870240042133, dated 05 / 17 / 2024, p. 58 / 86 51 / 72 Example 3: The ZZ-DTRBDHek and ZZ-Tat 22 to 57C(22 to 37)s fusion proteins induce, in vitro, the secretion of IL-6 and IL-12 by immune system cells. MATERIALS AND METHODS
[132] Mouse C57BL / 6 splenocytes are resuspended at 2x10⁶ cells / mL in RPMI medium, 10% FCS and 1% penicillin / streptomycin. 100 μL of the cell suspension are distributed in a 96-well plate in the presence or absence of molecular complexes (ZZ, DTRBD, ZZ-DTRBDhek, or ZZ-Tat 22 to 57C(22 to 37)s), incubated to a final 1 μM. After 24 h of incubation, the supernatants are collected for ELISA assay of IL-6 and IL-12 cytokines performed according to the manufacturer's instructions (R&D no. DY406-05 and DY419). RESULTS
[133] The inventors wondered if molecular complexes could induce the activation of immune system cells. Since cell activation can lead to cytokine secretion, the inventors decided to evaluate, in vitro, the presence of two cytokines in supernatants resulting from the incubation of mouse splenocytes with molecular complexes and different control proteins. The first cytokine is IL-6, as it represents important inflammatory cytokines for initiating the immune response. The second is IL-12, as it is crucial for inducing immune responses from cells. The inventors verified these two cytokines in increased quantities in the supernatants resulting from incubation with ZZ-DTRBDhek, indicating that this molecular complex induces splenocyte activation (Fig. 4).In contrast, they did not observe an increased amount of cytokines in the supernatants resulting from incubation with free ZZ or free DTRBD, indicating that the dual domain for Ig binding and the heparan sulfate binding domain cannot activate immune cells on their own. These results therefore demonstrate that... Petition 870240042133, dated 05 / 17 / 2024, page 59 / 86 52 / 72 ZZ-DTRBDHek is capable of inducing the activation of immune system cells, and indications suggest that the association of the dual Ig-binding domain and the DTRBD HS-binding domain is absolutely necessary for this effect.
[134] The inventors proceeded according to a principle similar to that described in the previous paragraph, in order to evaluate whether ZZ-Tat 22 to 57C(22 to 37)s is capable of activating immune system cells and whether the association of ZZ and the Tat domain involved in binding to heparan sulfates is absolutely necessary for the stimulatory effect. For this, they used, in particular, a peptide, called TatCY49-57, which contains the basic Tat region and therefore represents the interaction of Tat and its derivatives with heparan sulfates. They incubated mouse splenocytes with ZZ, TatCY49-57, ZZ + TatCY49 to 57 and ZZTat 22 to 57C(22 to 37)s, respectively. They then evaluated the presence of IL-6 and IL-12 in the supernatants. They verified these two cytokines in the supernatants resulting from incubation with ZZ-Tat 22 to 57C(22 to 37)s but not in the supernatants resulting from incubation with ZZ, TatCY49-57, ZZ + TatCY49 to 57 (Fig. 5).These results demonstrate, therefore, that ZZ-Tat 22 to 57C(22 to 37)s is capable of inducing the activation of immune system cells and that this characteristic is not shared by the free forms, ZZ and TatCY49-57, indicating that the association of the dual Ig-binding domain and the basic Tat region responsible for HS binding is absolutely necessary for the effect. Example 4: A molecular complex i) remains capable of triggering the secretion of IL-6 and IL-12 by immune system cells when its ZZ domain is replaced by BB, ii) has increased stimulatory capabilities when it consists of oligomeric forms. MATERIALS AND METHODS
[135] C57BL / 6 mouse splenocytes are resuspended at 2x106 cells / mL in RPMI medium, 10% FCS and 1% penicillin / streptomycin. 100 μL Petition 870240042133, dated 05 / 17 / 2024, pp. 60 / 86 53 / 72 of the cell suspension are distributed in a 96-well plate in the presence or absence of different molecular complexes (ZZ-DTRBDhek, BB-DTRBDhek, ZZ-DTRBDcoli and BB-DTRBDcoli) incubated at a final concentration of 1 μM. After 24 h of incubation, the supernatants are collected for ELISA assay of the cytokines IL-6 and IL-12 performed following the manufacturer's instructions (R&D No. DY406-05 and No. DY419). RESULTS
[136] The work described in example 3 was carried out with two molecular complexes containing the double ZZ domain. This double domain, which binds to the Fc of Ab, can thus target Ab located on the surface of APCs. The inventors then wondered whether molecular complexes that can jointly target the Fc region and the Fab region of Ig could also be capable of activating immune system cells. To this end, they focused on the double BB domain derived from the A protein of Staphylococcus aureus, which has the particular characteristic of being able to bind to the Fc region of Ab in the same way as Z, but also to the Fab region of Ab, unlike ZZ (Jansson B. et al., Fems Immunol. Med. Microbiol. 1998, 20:69-78). They prepared the BBDTRBHek and BB-DTRBDcoli complexes described in Example 1 and compared them with ZZDTRBDHek and ZZ-DTRBDcoli for their ability to induce the secretion of IL-6 and IL-12 cytokines in vitro when incubated with murine splenocytes.
[137] Since the inventors observed that ZZ-DTRBD and BB-DTRBD are in oligomeric form after their expression in HEK cells (see Fig. 1), while they are monomeric after expression in E. coli, this work also made it possible to evaluate whether the oligomerization state could affect the ability to induce the immune system.
[138] The inventors observed that the supernatants resulting from incubation with ZZ-DTRBDhek contained higher amounts of cytokines than those resulting from incubation with BB-DTRBDhek (Fig. 6). Similarly, the Petition 870240042133, dated 05 / 17 / 2024, pp. 61 / 86 54 / 72 supernatants resulting from incubation with ZZ-DTRBDcoii contained higher amounts of cytokines than those resulting from incubation with BB-DTRBDcoli. These results demonstrate that a molecular complex containing BB remains capable of inducing cytokine secretion in vitro, but to a lesser extent than a molecular complex containing ZZ. These data therefore indicate that the activation effect may be mediated by molecular complexes containing domains capable of binding to different sites on Ab.
[139] Comparison of cytokine content in supernatants based on the type of cell used (i.e., HEK vs. E. coli) to produce the molecular complexes demonstrated the difference in stimulatory efficacy depending on the type of production. In fact, in the supernatants resulting from incubation with complexes from HEK cells (ZZ-DTRBDhek, BBDTRBHek), IL-6 and IL-12 are present in greater quantities than those resulting from incubation with complexes resulting from expression in E. coli (ZZDTRBDcoli and BB-DTRBDcoli) (Fig. 6). Since the proteins resulting from expression in HEK cells are mainly oligomeric (see Fig. 1), the inventors deduced that the immune system is induced more effectively when the molecular complexes have a high degree of oligomerization. Example 5: Isolated dendritic cells secrete IL-6 and IL-12 when incubated in the presence of ZZ-DTRBDhek. MATERIALS AND METHODS
[140] A C57BL / 6J mouse is euthanized, then its spleen is recovered in RPMI medium, 10% FCS and 1% penicillin / streptomycin. The spleen is perfused with 3 mL of 2 mg / mL collagenase D in 0.5% HBSS and BSA and then incubated for 30 minutes at 37 °C. Splenocytes are recovered and magnetic sorting for dendritic cells (DCs) is performed according to the manufacturer's instructions (Miltenyi Biotec No. 130-100-875). The DCs are Petition 870240042133, dated 05 / 17 / 2024, pp. 62 / 86 55 / 72 cells were centrifuged for 5 minutes at 4 °C to 390 xg and then resuspended at 2 x 10⁶ cells / mL in RPMI medium, 10% FCS, and 1% penicillin / streptomycin. 100 μL of the cell suspension (200,000 cells) were placed in a 96-well round-bottom plate, and 100 μL of RPMI medium, 10% FCS, and 1% penicillin / streptomycin were added in the absence or presence of ZZDTRBDhek (final 0.6 μM). The cells were incubated for 24 hours at 37 °C, then the supernatants were collected for ELISA assay of IL-6 and IL-12 cytokines according to the manufacturer's instructions (R&D No. DY406-05 and No. DY419). RESULTS
[141] The establishment of immune defense mechanisms depends on collaboration between different partner cells. Among these, dendritic cells (DCs) represent the APCs playing a central role. This is because they contribute to activating other cell types, through direct interactions or through cytokines they secrete. To assess whether ZZ-DTRBD induces cytokine secretion by DCs, DCs were purified from splenocytes of C57BI / 6 mice. Then, these DCs were incubated for 24 h in the presence or absence of ZZ-DTRBD, then the supernatants were removed to test for the presence of IL-6 and IL-12 (Fig. 7). The amount of IL-6 present in the supernatants resulting from incubation with ZZ-DTRBDhek is approximately 5 times greater than that found in the supernatants resulting from incubation without a molecular complex.A large amount of IL-12 (approximately 8700 pg / mL) is also detected in the supernatants resulting from incubation with ZZ-DTRBDhek, but practically none in those resulting from incubation without a molecular complex. These data therefore indicate that ZZ-DTRBD causes the secretion of IL-6 and IL-12 by murine dendritic cells and may thus contribute to the establishment of immunological defense mechanisms. Petition 870240042133, dated 05 / 17 / 2024, pp. 63 / 86 56 / 72 Example 6: The proteins ZZ-DTRBD and ZZ-Tat 22 to 57C(22 to 37)s are capable of inducing dendritic cells in mice. MATERIALS AND METHODS
[142] Three groups of eight C57BL / 6 mice were injected three times, at three-day intervals, with 100 μL of PBS in the absence or presence of ZZDTRBDhek (5 nmol per mouse) or ZZ-Tat 22 to 57C(22 to 37)s (10 nmol per mouse), respectively. 24 hours after the final injection, the animals were euthanized, and the spleens were collected to retrieve splenocytes. The cells were resuspended in 50 μL of labeling buffer (PBS, 0.5% BSA, and 2 mM EDTA) containing different Ab mixtures. The cells were then incubated for 20 minutes at 4 °C in the dark and then washed twice in PBS, 0.5% BSA, and 2 mM EDTA. The cells were then fixed for 20 minutes at 4 °C in 100 μL of 4% PFA buffer and then washed in PBS, 0.5% BSA, and 2 mM EDTA. They were finally resuspended in 200 μL of PBS, 0.5% BSA, and 2 mM EDTA and then analyzed using a BD FACSAria™ flow cytometer. The cells were analyzed by flow cytometry.cDC-CD8+ are identified as CD11altoB220-CD8+CD11b-, cDC-CD11b+ are identified as CD11altoB220-CD8-CD11b+, and pDC are identified as... CD11cintCD317+CD11b+.
[143] The Ab mixtures used for dendritic cell phenotype analysis are as follows: B220-FITC (n° 103206, 1 / 200), CD11c-PE-Cy7 (n° 117318, 1 / 200), CD317-APC (n° 127016, 1 / 100), CD11b-APC-Cy7 (n° 101226, 1 / 800), CD8a-PerCP-Cy5.5 (n° 100734, 1 / 200), Live Dead Violet (ThermoFischer n° L34964, 1 / 1000). RESULTS
[144] Because molecular complexes preferentially bind to APCs in vitro and induce cytokine secretion, the inventors wondered Petition 870240042133, dated 05 / 17 / 2024, pp. 64 / 86 57 / 72 whether such complexes could induce APC expansion in mice. To evaluate this aspect, the inventors injected three groups of 8 C57BI / 6 mice with a PBS solution in the presence or absence of ZZ-DTRBDhek or ZZ-Tat 22 to 57C(22 to 37)s. They then euthanized the animals and collected spleen samples to assess the frequency of different dendritic cell subpopulations in splenocytes. As can be seen in Fig. 8, the three murine DC populations (i.e., DC-CD8+, DC-CD11b+, and pDC) are present in the spleens of the group of mice injected only with PBS. However, the frequency of these three cell types is significantly increased in the groups of animals injected with ZZ-DTRBDhek or ZZ-Tat 22 to 57C(22 to 37)s. These data therefore indicate that molecular complexes are capable of inducing the expansion of dendritic cells in vivo.Since these cells are central to initiating the immune response, these results strongly suggest that the complexes may thus promote the induction of immune response mechanisms. Example 7: ZZ-DTRBHek induces the secretion of IL-6 and IL-12 by human dendritic cells in vitro. MATERIALS AND METHODS Isolation of human dendritic cells and incubation for the study of IL-6 and IL-12 secretion.
[145] A layer of leukocytes-platelets is diluted to ½ in AIM V medium, then incubated overnight at room temperature with shaking. 15 mL of histopac medium are then added to 4 leucosep tubes, to which 4 x 25 mL of diluted blood are added. The tubes are centrifuged without restrictions for 15 minutes at room temperature at 1000 x g. Peripheral blood mononuclear cell (PBMC) rings are recovered and washed in 2 mM PBS and EDTA without calcium or magnesium. The PBMCs are centrifuged at Petition 870240042133, dated 05 / 17 / 2024, pp. 65 / 86 58 / 72 150 x g for 10 minutes at room temperature, then a red blood cell lysis buffer (NH4C 8.3 mg / mL, NaHCO3 0.84 mg / mL, EDTA 0.1 mM) is added and incubated for 10 minutes at 4 °C. 40 mL of PBS are added and then the cells are centrifuged for 10 minutes at room temperature at 150 x g. The DCs are then sorted according to the manufacturer's instructions (Miltenyi Biotec No. 130-091-379). The DCs are centrifuged for 5 minutes at 4 °C at 390 x g and then resuspended at 2 x 10⁶ cells / mL in RPMI medium, 10% FCS and 1% penicillin / streptomycin. 100 μL of sorted DCs (200,000 cells) are placed in a 96-well plate and 100 μL of RPMI medium, 10% FCS and 1% penicillin / streptomycin are added in the absence or presence of ZZ-DTRBDhek (final 1 μM). The cells are incubated for 24 hours at 37 °C, then the supernatants are collected for ELISA assay of IL-6 and IL-12 cytokines according to the manufacturer's instructions (R&D no. DY206-05 and DY1270-05). RESULTS
[146] To assess whether ZZ-DTRBDhek can induce, in vitro, the secretion of IL-6 and IL-12 by DCs from healthy human donors, the presence of these two cytokines in the culture supernatants of these cells was evaluated after 24 h of incubation. As can be seen in Fig. 9, IL-6 is found in approximately 10 times greater quantity in the supernatants resulting from incubation in the presence of ZZ-DTRBDhek than in the supernatants resulting from incubation in the absence of the fusion protein. IL-12 is present in large quantities (2400 pg / mL) in the supernatants resulting from incubation of DCs in the presence of ZZ-DTRBDhek and in very low quantities (8 pg / mL) in those resulting from incubation in the absence of the molecular complex. All these data indicate, therefore, that ZZ-DTRBD induces an increase in the secretion of IL-6 and IL-12 by human DCs. ZZ-DTRBD could therefore contribute to the Petition 870240042133, dated 05 / 17 / 2024, pages 66 / 86 59 / 72 establishment of immune defense mechanisms in humans that are linked to the secretion of these cytokines. Example 8: ZZ-DTRBD and ZZ-Tat 22 to 57C(22 to 37)s retard the progression of colorectal tumor growth. MATERIALS AND METHODS Study of the effect of the CpG / Poly l:C adjuvant mixture on tumor growth in a murine colorectal cancer cell line.
[147] Two groups of eight C57BL / 6 mice were injected subcutaneously in the paw with 0.5 M MC38 cells. The mice were then either not injected (controls) or injected with the adjuvant mixture CpG-B 1018 / Poly l:C (30 μg for each adjuvant) three and six days later. Tumor growth was monitored by measuring the tumors using calipers. Upon reaching the cessation criterion, they were euthanized. Study of the effect of the molecular complex ZZ-DTRBDHek, injected in the absence or presence of adjuvant, on tumor growth in a murine colorectal cancer cell line.
[148] Three groups of six C57BL / 6 mice were injected subcutaneously in the paw with 0.5 M MC38 cells. Three, six, and nine days later, the mice are either not injected (controls) or injected with ZZDTRBDhek (2 nmol per mouse) in the absence or presence of CpG-B 1018 + Poly l:C (30 μg for each adjuvant per mouse). The mice are monitored individually for 15 days (tumor measurements using calipers) before euthanasia. Comparison of the effect of an anti-PD-1 antibody and the molecular complexes ZZDTRBDhek and ZZ-Tat 22 to 57C(22 to 37)s on the tumor growth of a murine colorectal cancer cell line.
[149] Four groups of eight C57BL / 6 mice were injected Petition 870240042133, dated 05 / 17 / 2024, pp. 67 / 86 60 / 72 subcutaneously in the paw with 0.5 M of MC38 cells. Three, six, and nine days later, the mice are either not injected (controls) or are injected with anti-PD-1 antibody (Euromedex No. BE0146-100MG, clone RMP1-14), ZZDTRBDhek, or ZZ-Tat 22 to 57C(22 to 37)s (0.96 nmol per mouse) in the presence of CpG-B 1018 + Poly l:C (30 μg for each adjuvant per mouse). The mice are monitored individually over time (tumor measurements using calipers). Upon reaching the cessation criterion, they are euthanized. RESULTS
[150] To assess whether molecular complexes can impact tumor growth, studies were conducted in a syngeneic murine cancer model. This model is based on a colon tumor cell line, referred to as MC38 and C57BI / 6 mice. Cancer induction is caused by injecting 500,000 MC38 cells per mouse.
[151] First, the impact on tumor growth of the CpG1018 / Poli l:C adjuvant mixture was evaluated. As can be seen in Fig. 10A, compared with the untreated group (control), tumor growth is practically unchanged in the group of mice injected with the CpG1018 / Poli l:C mixture. These data indicate, therefore, that the adjuvant mixture alone cannot retard the growth of this colorectal tumor.
[152] Secondly, the impact on tumor growth of ZZDTRBDhek injected alone or in the presence of the adjuvant mixture CpG1018 / Poli l:C was evaluated. As can be seen in Fig. 10B, compared with the untreated (control) group, tumor growth is delayed on day 8 and day 10 in the group injected with ZZ-DTRBDhek without adjuvant. The effect is even greater in the group treated with ZZ-DTRBDhek and the adjuvant mixture CpG1018 / Poli l:C. In fact, in this group, tumor growth is delayed throughout the entire period of Petition 870240042133, dated 05 / 17 / 2024, pp. 68 / 86 61 / 72 observation of the animals (day 6 to day 15). All these data indicate, therefore, that ZZ-DTRBDHek has an impact on the growth of the MC38 cell line and that this effect is amplified when mixed with the adjuvant CpG1018 / Poli l:C.
[153] In another series of experiments, the effect on MC38 tumor growth in C57BI / 6 mice was compared for the following treatments: ZZ-DTRBDhek / CpG1018 / poIí l:C, ZZ-Tat 22 a 57C(22 a 37)S / CpG1018 / poly l:C, Ab anti-PD-1. As can be seen in Figs. 11A and 11B, treatment with anti-PD-1 Ab has no significant impact on tumor growth compared to the control group. In contrast, mice injected with ZZ-DTRBDhek / CPG1018 / poIí l:C and ZZ-Tat 22 a 57C(22 a 37)S / CpG1018 / poly l:C respectively exhibit reduced tumor growth. This slowdown in tumor growth leads to an increase in the survival of animals in these two groups (Fig. 11C). Example 9: CD4+ activated monocytes and lymphocytes can be induced by molecular complexes that target, respectively, the surface molecule DEC205 and Fcγ receptors. MATERIALS AND METHODS
[154] To prepare a molecular complex targeting the DEC205 molecule, an anti-DEC205 antibody was used (BioLegend; clone NLDC-145, ref BLE138202). It was incubated in the absence or presence of ZZ-Tat 22 at 57C(22 to 37)sa at a fixed concentration (0.2 μM for each molecule) for 24 hours in RPMI medium without FCS. The ability of the ZZ region to bind to the Fc region of the anti-DEC205 antibody enabled the formation of a non-covalent molecular complex, referred to as anti- DEC205 / ZZ-Tat 22 to 57C(22 to 37)s. The same protocol was used to form a complex between the ZZ molecule and the anti-DEC205 antibody, referred to as antiDEC205 / ZZ. Petition 870240042133, dated 05 / 17 / 2024, pp. 69 / 86 62 / 72
[155] To prepare a molecular complex targeting FCgamma receptors, a non-specific human polyclonal antibody was used. This Ab was incubated with ZZ-Tat 22 to 57C(22 to 37)s or ZZ, following a protocol identical to that used for the anti-DEC205 Ab. It was thus possible to form a non-covalent molecular complex, referred to as lgG / ZZ-Tat 22 to 57C(22 to 37)s or an IgG / ZZ complex.
[156] Human PBMCs prepared as described in Example 7 were then incubated in the absence or presence of the following compounds: Ab anti-DEC205 / ZZ-Tat 22 to 57C(22 to 37)s, IgG / ZZ-Tat 22 to 57C(22 to 37)s, anti-DEC205 / ZZ, IgG / ZZ ZZ-DTRBDhek and anti-DEC205 and free IgG (final concentration of 0.1 μM for each compound). In these experiments, PBMCs were also incubated with ZZ-Tat 22 to 57C(22 to 37)s and free ZZ proteins at a concentration of 1 μM. After 24 h, the cells were collected and labeled using fluorescent Ab, allowing the identification of monocytes (CD14, anti-CD14-BV605, Biolegend), CD4+ T lymphocytes (CD4, anti-CD4-PerCP-Cy5.5, Biolegend), and the CD69 molecule (anti-CD69BV785, Biolegend). After 30 minutes of incubation, the PBMCs were fixed in a solution containing 4% paraformaldehyde and analyzed by flow cytometry. RESULTS
[157] The previous examples show that molecular complexes targeting Ab can effectively induce certain immune response mechanisms and effectively retard tumor growth. Abs located on the surface of APCs are the molecules targeted by these complexes. However, APCs express a large number of other molecules that may also represent targets for molecular complexes according to the invention. The inventors, therefore, wondered whether molecular complexes targeting HS and receptors other than immunoglobulins located on the surface of APCs could also activate these cells. To evaluate this aspect, they chose to evaluate two types of Petition 870240042133, dated 05 / 17 / 2024, pp. 70 / 86 63 / 72 receptors. The first is the DEC205 protein, which is a lectin selectively expressed in humans by monocytes and certain populations of dendritic cells (Kato M. et al. 2006, Int. Immunol., 18:857-869). The second is the FCgamma receptor, most forms of which are expressed by monocytes and certain populations of dendritic cells.
[158] The inventors then prepared two molecular complexes that can target these receptors, respectively. To target the DEC205 protein, they used a monoclonal antibody specific to this receptor, which they complexed with the ZZ-Tat 22 to 57C(22 to 37)s fusion protein. They referred to this molecular complex as anti-DEC205 / ZZ-Tat 22 to 57C(22 to 37)s. To target the Fc receptors, they used a non-specific human polyclonal IgG antibody that can interact with these receptors through its Fc domain. They formed a molecular complex between this IgG and ZZ-Tat 22 to 57C(22 to 37)s, referred to as IgG / ZZTat 22 to 57C(22 to 37)s. These two aforementioned molecular complexes therefore have the ability to bind to APC receptors and heparan sulfates via the Tat 22 to 57C(22 to 37)s domain of ZZ-Tat 22 to 57C(22 to 37)s. In these molecular complexes, the two proteins are non-covalently associated through their respective Fc and ZZ domains.Therefore, ZZ can no longer target immunoglobulins located on the surface of APCs, as it is already interacting with Ab. The inventors also prepared two complexes, respectively referred to as anti-DEC205 / ZZ and IgG / ZZ, free of the Tat 22 to 57C(22 to 37)s region of heparan sulfate binding, in order to use them as controls in subsequent activation experiments.
[159] Since the DEC205 molecule and Fc receptors are expressed by monocytes, the inventors wondered if molecular complexes could enable the activation of this subpopulation of APCs. To this end, they incubated PBMCs in the absence or presence of a fixed concentration (0.1 μM) of anti Petition 870240042133, dated 05 / 17 / 2024, pp. 71 / 86 64 / 72 DEC205 / ZZ-Tat 22 to 57C(22 to 37)s, IgG / ZZ-Tat 22 to 57C(22 to 37)s, anti-DEC205 / ZZ, IgG / ZZ, anti-DEC205, IgG, respectively. They also incubated ZZ-Tat 22 to 57C(22 to 37)s and free ZZ proteins at a concentration of 1 μM to evaluate the effect of ZZ-Tat 22 to 57C(22 to 37)s at a concentration identical to that considered activating in Examples 3, 4, and 5. After 24 h, they assessed the proportion of activated monocytes and CD4+ T lymphocytes. As can be seen in Fig. 12A, ZZ does not modify the proportion of activated monocytes in PBMCs, while it is significantly increased by ZZ-Tat 22 to 57C(22 to 37)s, indicating that this molecular complex enables the activation of human APCs. The proportion of activated cells is reduced with the anti-DEC205 antibody, free or included in the anti-DEC205 / ZZ complex. In contrast, the proportion of activated monocytes is increased in the presence of the anti-DEC205 / ZZ-Tat 22 to 57C(22 to 37)s complex.Similar behavior is observed when CD4+ T lymphocytes are considered (Fig. 12B). These data indicate, therefore, that an Ab targets APCs and, lacking the ability to activate them, can become capable of inducing them when included in a molecular complex that also allows targeting of HS.
[160] Analysis of the activation state of monocytes after incubation with free human IgG shows that this Ab allows an increase in the proportion of activated monocytes. IgG / ZZ does not allow a significant increase in the proportion of activated cells. In contrast, the number of activated monocytes is more than twice as high when PBMCs are incubated with the IgG / ZZ-Tat 22 to 57C(22 to 37)s molecular complex. Similar behavior is observed when CD4+ T lymphocytes are considered (Fig. 12B). These data indicate, therefore, that an Ab targeting Fcγ receptors on the surface of APCs is capable of activating them, but that the activation effect is increased when the Ab is included in a molecular complex enabling targeting of HS as well.
[161] Interestingly, these results show a combined increase in Petition 870240042133, dated 05 / 17 / 2024, pp. 72 / 86 The 65 / 72 ratio of activated monocytes to T lymphocytes indicates that molecular complexes induce various cell actuators that play a central role in immune defense mechanisms. Example 10: Molecular complexes that target dendritic cells induce, in vitro, the secretion of IL-6 by cells of the immune system. MATERIALS AND METHODS
[162] To prepare molecular complexes that target DCs, three antibodies specific to the molecules expressed by DCs were used. The first Ab (BD reference 555538), referred to as anti-CD74 Ab, targets the CD74 molecule. The second Ab (BD reference 551186), referred to as anti-CD209 Ab, targets the CD209 molecule. The third Ab (BD reference 552501), referred to as anti-CD275 Ab, targets the CD275 molecule.
[163] Each of these three Ab (30 nM for each molecule) was incubated in the absence or presence of ZZ-Tat 22 to 57C(22 to 37)s or ZZ (5 nM for each molecule), for 24 hours at 4 °C in RPMI medium and 5% human serum AB. The ability of the ZZ region to bind to the Fc region of these Ab enabled the formation of different non-covalent molecular complexes, referred to as anti-CD74 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD209 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD275 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD74 / ZZ, anti-CD209 / ZZ and anti-CD275 / ZZ, respectively.
[164] Human PBMCs are resuspended at 5x106 cells / mL in RPMI medium and 5% human serum AB. 100 μL of the cell suspension were distributed in a 96-well plate in the presence or absence of free Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37) and also the molecular complexes. After 24 h of incubation, the supernatants are collected for IL-6 cytokine ELISA assay performed according to the manufacturer's instructions (R&D No. DY406-05). RESULTS
[165] The inventors wondered if molecular complexes that target Petition 870240042133, dated 05 / 17 / 2024, pp. 73 / 86 66 / 72 three molecules expressed by DCs could induce the activation of immune system cells. Since cell activation can lead to cytokine secretion, the inventors decided to evaluate the presence of IL-6 in vitro. They verified this cytokine in the supernatants resulting from incubation with ZZ-Tat 22 to 57C(22 to 37)s, but not in the supernatants resulting from incubation with ZZ. They did not verify any in the supernatants resulting from incubation of PBMCs with the free anti-CD74 Ab (Fig. 13A), indicating that this Ab cannot induce activation when in its free form. The inventors observed that IL-6 secretion is increased when PBMCs are incubated with the anti-CD74 / ZZ complex, indicating that the dual ZZ domain allows activation mediated by this Ab (Fig. 13A).However, the secretion of this cytokine is even stronger with anti-CD74 / ZZ-Tat 22 to 57C(22 to 37)s, indicating that the addition of the Tat region, which allows HSPG binding, enables increased cell activation mediated by this complex.
[166] The inventors observed that free anti-CD209 and anti-CD275 antibodies are capable of inducing IL-6 secretion when incubated with PBMCs (Figs. 13B and 13C). When these two antibodies are respectively complexed with ZZ (anti-CD209 / ZZ and anti-CD275 / ZZ), secretion of this cytokine is also observed. However, this secretion is increased when these two antibodies are complexed with ZZ-Tat 22 to 57C(22 to 37)s, indicating that the activation power can be increased when the molecular targeting complexes are able to bind to HSPGs. Example 11: A molecular complex directed against the CD335 receptor expressed by NK and NKT cells induces, in vitro, an increase in the proportion of activated NK and NKT cells. MATERIALS AND METHODS
[167] To prepare molecular complexes that target the CD335 molecule on the surface of NK and NKT cells, an Ab (Origene AM31284AF-N), Petition 870240042133, dated 05 / 17 / 2024, pp. 74 / 86 67 / 72 referred to as Ab anti-CD335. This Ab was incubated at 30 nM in the absence or presence of ZZ-Tat 22 at 57C(22 to 37)s or ZZ (5 nM for each molecule), for 5 hours at 37 °C in RPMI medium and 5% human serum Ab. The ability of the ZZ region to bind to the Fc region of these Abs enabled the formation of two molecular complexes, referred to as anti-CD335 / ZZ-Tat 22 at 57C(22 to 37)s and anti-CD335 / ZZ, respectively.
[168] Human PBMCs are resuspended at 5x106 cells / mL in RPMI medium and 5% human serum AB. 100 μL of the cell suspension were distributed in a 96-well plate in the presence or absence of antiCD335, ZZ or ZZ-Tat Ab 22 to 57C(22 to 37) and also the molecular complexes. After 18 h, the cells were collected and labeled with fluorescent Ab, allowing the identification of NK cells (CD56+, Biolegend reference 362510, 1 / 100 dilution), NKT cells (CD56+, Biolegend reference 362510; CD3+ cells; Miltenyi ref 130-113-136, 1 / 200 dilution), and the CD69 molecule (Biolegend reference 310932, 1 / 100 dilution). After 30 minutes of incubation, the PBMCs were fixed in a solution containing 4% paraformaldehyde and analyzed by flow cytometry. RESULTS
[169] The inventors wondered whether molecular complexes targeting the CD335 molecule expressed on the surface of NK and NKT cells could induce activation of these two cell types. To evaluate this, they used the anti-CD335 antibody in isolated form or included in a molecular complex. They incubated PBMCs in the absence or presence of the different mixtures. Since NK and NKT cells play a crucial role in immune defense mechanisms, after 18 h of incubation they assessed the proportion of activated NK and NKT cells by monitoring the expression of the co-stimulatory molecule CD69.
[170] As can be seen in figure 14, ZZ, the isolated anti-CD335 Ab and the Petition 870240042133, dated 05 / 17 / 2024, pp. 75 / 86 The 68 / 72 anti-CD335 / ZZ complex does not increase the proportion of NK (A) or NKT (B) cells expressing CD69 in PBMCs. Different behavior is observed with free ZZ-Tat 22 to 57C(22 to 37)s. In fact, this molecular complex does not increase the proportion of NKT cells expressing CD69, but it does increase the percentage of NK cells expressing this marker, indicating that the association of ZZ and the HS ligand in the ZZ-Tat 22 to 57C(22 to 37)s complex allows for increased NK cell activation. The anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s molecular complex impacts the activation of both cell subpopulations. In fact, it increases the proportion of NK and NKT cells expressing CD69. All these data indicate, therefore, that the anti-CD335 antibody does not have the capacity to activate both types of cells, but it may become capable of inducing them when included in a molecular complex that also makes it possible to target HS. Example 12: Molecular complexes targeting CD56 (A) and CD336 (B) molecules expressed by NK and NKT cells respectively induce an increase in the proportion of activated NKT cells in vitro. MATERIALS AND METHODS
[171] To prepare molecular complexes that target CD56 and CD336 molecules on the surface of NK and NKT cells, anti-CD56 Ab (Biolegend reference 304622) targeting the CD56 molecule and anti-CD336 Ab (Origene AM50346PU-N) targeting the CD336 molecule.
[172] These Abs were incubated at 30 nM in the absence or presence of ZZ-Tat 22 at 57C(22 to 37)s or ZZ (5 nM for each molecule), for 5 hours at 37 °C in RPMI medium and 5% human serum AB. The ability of the ZZ region to bind to the Fc region of these Abs enabled the formation of four molecular complexes, referred to as anti-CD56 / ZZ-Tat 22 at 57C(22 to 37)s, anti-CD56 / ZZ, anti-CD336 / ZZ-Tat 22 at 57C(22 to 37)s, and anti-CD336 / ZZ, respectively.
[173] Human PBMCs are resuspended at 5x106 cells / mL in medium Petition 870240042133, dated 05 / 17 / 2024, pp. 76 / 86 69 / 72 RPMI and 5% human serum AB. 100 μL of the cell suspension were distributed in a 96-well plate in the presence or absence of isolated forms of anti-CD56 Ab, anti-CD336 Ab, anti-CD336 Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37) and also non-covalent molecular complexes. After 18 h, the cells were collected, labeled with fluorescent Ab described in Example 11 which allows identification of NKT cells (CD56+CD3+) and the CD69 molecule. After 30 minutes of incubation, the PBMCs were fixed in a solution containing 4% paraformaldehyde and analyzed by flow cytometry. RESULTS
[174] The inventors wondered whether molecular complexes targeting the expressed molecules, CD56 and CD336, could induce NKT cell activation. To evaluate this, they used anti-CD56 and anti-CD336 antibodies in isolated form or included in a molecular complex. They incubated PBMCs in the absence or presence of the different mixtures. After 18 h of incubation, they assessed the proportion of activated NKTs by monitoring the expression of the co-stimulatory molecule CD69.
[175] As can be seen in Figure 15, ZZ, ZZ-Tat 22 to 57C(22 to 37)s, the anti-CD56 antibody, the isolated anti-CD336 antibody, and the anti-CD336 / ZZ complex do not increase the proportion of NKT cells expressing CD69 in PBMCs. Different behavior is observed with the molecular complexes anti-CD56 / ZZ-Tat 22 to 57C(22 to 37)S (Fig. 15A), anti-CD336 / ZZ-Tat 22 to 57C(22 to 37)s (Fig. 15B). In fact, an increase in the proportion of NKT cells expressing CD69 is observed when these two molecular complexes are incubated with PBMCs. All these data indicate, therefore, that isolated anti-CD56 and anti-CD336 antibodies do not have the capacity to activate NKT cells, but may become capable of inducing them when included in a molecular complex that also targets HS. Example 13: Molecular complexes that target NK and NKT cells. Petition 870240042133, dated 05 / 17 / 2024, pp. 77 / 86 70 / 72 induce, in vitro, the secretion of IL-6 by cells of the immune system. MATERIALS AND METHODS
[176] To prepare molecular complexes targeting NK and NKT cells, the three antibodies described in Examples 10 and 11 were used. Each of these three Ab (30 nM for each molecule) was incubated in the absence or presence of ZZ-Tat 22 to 57C(22 to 37)s or ZZ (5 nM for each molecule), for 24 hours in RPMI medium and 5% human serum AB. The ability of the ZZ region to bind to the Fc region of these antibodies enabled the formation of different non-covalent molecular complexes, referred to as anti-CD56 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD336 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CD56 / ZZ, anti-CD335 / ZZ and anti-CD336 / ZZ, respectively.
[177] Human PBMCs are resuspended at 5x106 cells / mL in RPMI medium, 5% human serum AB. 100 μL of the cell suspension are distributed in a 96-well plate in the presence or absence of Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37)s free and also the molecular complexes. After 24 h of incubation, the supernatants are collected for IL-6 cytokine ELISA assay performed according to the manufacturer's instructions (R&D No. DY406-05). RESULTS
[178] The inventors wondered if molecular complexes targeting NK and NKT cells could induce the activation of immune system cells. Since cell activation can lead to cytokine secretion, the inventors decided to evaluate the presence of IL-6 in vitro. They verified this cytokine in the supernatants resulting from incubation with ZZ-Tat 22 to 57C(22 to 37)s but not in the supernatants resulting from incubation with ZZ. They did not verify any IL-6 in the supernatants resulting from incubation of PBMCs with free anti-CD56 and anti-CD335 antibodies (Fig. 16A and 16B), indicating that these two proteins cannot induce activation when they are in the form Petition 870240042133, dated 05 / 17 / 2024, pp. 78 / 86 71 / 72 free. In contrast, they detected the cytokine in the supernatants resulting from incubation with the anti-CD336 antibody (Fig. 16C), indicating that, in its free form, this Ab has stimulatory activity. The inventors observed, for the three Abs, increased IL-6 secretion when PBMCs are incubated respectively with the anti-CD56 / ZZ-Tat 22 to 57C(22 to 37)s complexes (Fig. 16A), anti-CD335 / ZZ-Tat 22 to 57C(22 to 37)s (Fig. 16B) and anti-CD336 / ZZ-Tat 22 to 57C(22 to 37)s (Fig. 16C). These data therefore indicate that molecular complexes targeting NK cells and HSPGs can induce effective immune cell activation. Example 14: Molecular complexes targeting immune checkpoints (ICPs) induce, in vitro, the secretion of IL-6 by immune system cells. MATERIALS AND METHODS
[179] To prepare molecular complexes that target ICPs, three antibodies specific to molecules considered to be ICPs were used. The first Ab (BioXCell reference BE0190), referred to as Ab antiCTLA-4, targets the CTLA-4 molecule. The second Ab (BioXCell reference BE0285), referred to as Ab anti-PD-L1, targets the PD-L1 molecule. The third Ab (R&D reference MAB10542), referred to as Ab anti-OX40, targets the OX40 molecule.
[180] Each of these three Abs (30 nM for each molecule) was incubated in the absence or presence of ZZ-Tat 22 to 57C(22 to 37)s or ZZ (5 nM for each molecule), for 24 hours at 4 °C in RPMI medium, 5% human serum AB. The ability of the ZZ region to bind to the Fc region of these Abs enabled the formation of different non-covalent molecular complexes, referred to as anti-CTLA-4 / ZZ-Tat 22 to 57C(22 to 37)s, anti-PD-L1 / ZZ-Tat 22 to 57C(22 to 37)s, anti-OX40 / ZZ-Tat 22 to 57C(22 to 37)s, anti-CTLA-4 / ZZ, anti-PD-L1 / ZZ and anti-OX40 / ZZ, respectively.
[181] Human PBMCs were resuspended at 5x106 cells / mL in medium Petition 870240042133, dated 05 / 17 / 2024, pp. 79 / 86 72 / 72 RPMI, 5% human serum AB. 100 μL of the cell suspension were distributed in a 96-well plate in the presence or absence of free Ab, ZZ or ZZ-Tat 22 to 57C(22 to 37) and also the molecular complexes. After 24 h of incubation, the supernatants were collected for IL-6 cytokine ELISA assay performed according to the manufacturer's instructions (R&D No. DY406-05). RESULTS
[182] The inventors wondered whether molecular complexes targeting ICPs could induce the activation of immune system cells. Since cell activation can lead to cytokine secretion, the inventors decided to evaluate the presence of IL-6 in vitro. They found none in the supernatants resulting from the incubation of PBMCs with the three different free Ab or with free ZZ, indicating that these compounds cannot induce activation when in free form (Fig. 17A, 17B and 17C). In contrast, they found this cytokine in supernatants resulting from incubation with ZZ-Tat 22 to 57C(22 to 37)s, demonstrating that the association of the Ig-binding dual domain and the HS-binding domain Tat 22 to 57C(22 to 37)s allows immune system cells to be activated. However, the inventors observed that IL-6 secretion increases even further when PBMCs are incubated respectively with the anti-CTLA-4 / ZZ-Tat complexes 22 to 57C(22 to 37)s, (Fig.17A), anti-PD-L1 / ZZ-Tat 22 to 57C(22 to 37)S (Fig. 17B) and anti-OX40 / ZZ-Tat 22 to 57C(22 to 37)s (Fig. 17C). In contrast, IL-6 is absent from the supernatants resulting from incubation with anti-CTLA-4 / ZZ, anti-PD-L1 / ZZ or anti-OX40 / ZZ, indicating that the dual ZZ domain does not contribute to activation mediated by these antibodies. All these data therefore indicate that molecular complexes targeting ICPs and HSPGs can induce immune cell activation. Petition 870240042133, dated 05 / 17 / 2024, pages 80 / 86
Claims
1 / 2 CLAIMS 1. Use of a molecular complex or a composition comprising the molecular complex, characterized in that it is for the manufacture of an immunostimulant drug for the treatment of cancer, wherein said complex consists of a fusion protein comprising: a first linker which is a heparan sulfate-binding peptide expressed on the surface of antigen-presenting cells or NK or NKT cells selected from the group consisting of: Tat 22 to 57C(22-37)S of SEQ ID NO: 9 and diphtheria toxin R domain of SEQ ID NO: 5; and a second linker of an antigen-presenting cell or NK or NKT cell surface molecule which is a ZZ polypeptide of SEQ ID NO: 2 derived from protein A of S.aureus, wherein the ligands are linked together and the complex is free of a specific tumor antigen of the cancer to be treated, and wherein the molecular complex induces the activation and / or expansion of dendritic cells, monocytes, NK, NKT or T cells, and / or activates the secretion of IL-6 and / or IL-12 cytokines independently of the presence of a specific tumor antigen of the cancer to be treated.
2. Use according to claim 1, characterized in that said fusion protein comprises Tat 22 to 57C(22-37)S and the ZZ polypeptide, and the ZZ polypeptide is linked to an antibody selected from the group consisting of: an IgG and an antibody against DEC-205, DC-SIGN, CD74, CD275, CD56, CD335, CD336, CTLA-4, PD-L1 or OX40.
3. Use according to claim 1 or 2, characterized in that the composition additionally comprises at least one pharmaceutically acceptable carrier, a carrier substance and / or an adjuvant. Petition 870260093065, dated 10 / 09 / 2026, page 11 / 12 2 / 2 4. Use according to claim 3, characterized in that the adjuvant is a CpG oligodeoxynucleotide, polynosinic:polycyticidyl acid or a mixture of CpG oligodeoxynucleotide(s) and polynosinic:polycyticidyl acid and / or the carrier substance is a nanoparticle.
5. Use according to claim 3 or 4, characterized in that the composition additionally comprises an immune checkpoint inhibitor.
6. Use according to claim 5, characterized in that the immune checkpoint inhibitor is an anti-PD-1, an anti-PDL-1 or an anti-CTLA4.
7. Use in accordance with any of claims 1 to 6, characterized in that the cancer is selected from the group consisting of: breast cancer, colon cancer, prostate cancer, esophageal cancer, stomach cancer, lung cancer, ear, nose and throat cancer, skin cancer, ovarian cancer, uterine cancer, brain cancer, liver cancer or kidney cancer. Petition 870260093065, dated 10 / 09 / 2026, page 12 / 12
